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Abstract 
 
 
At early stages of life, infant immature intestine is not fully developed, exposing the new-
born to potential diseases. Compounds that can exert beneficial actions on the infant 
intestine are bioactive lactose-based oligosaccharides (LBOs). The natural source of LBOs 
is mother milk. When human milk is lacking, dietary supplementation with infant formula 
fortified with manufactured LBOs, such as galacto-oligosaccharides (GOS), is pursued. 
GOS have been shown to have several properties in common with HMOs. LBO 
composition and intestinal fate is extensively described for humans, whereas both aspects 
are hardly investigated for domestic animal. In this PhD thesis, composition of LBOs in 
equine and porcine colostrum were described and new structures were elucidated. The 
analysis were performed mainly using liquid chromatography with mass spectrometry and 
capillary electrophoresis with fluorescence detection. With these techniques novel milk 
oligosaccharides were found: seven equine milk oligosaccharides, of which four neutral and 
three acidic, and thirteen porcine milk oligosaccharides (PMOs), of which eight neutral and 
five acidic. High inter- and intra-individual variations were found for oligosaccharides 
present in equine and porcine milks. In vivo fermentation of PMOs was described analysing 
PMOs as found in fecal samples of piglets. The results were correlated to existing literature 
on HMOs. The presence of GOS and PMOs in blood, urine and fecal samples from an in 
vivo feeding trial with piglets was described. Intact GOS and milk oligosaccharides from 
the piglet diet, in addition to dietary oligosaccharides, were found in piglets’ blood and 
urine samples, as suggested from studies on HMO presence in infants’ blood and urine. All 
oligosaccharides were fermented/absorbed in vivo, not being detectable in the piglets’ fecal 
samples. GOS in vitro fermentation by piglet inoculum delineate a unique fermentation 
profile regarding GOS size consumption compared with GOS in vitro fermentation by 
human fecal inoculum. Similar degradation profile regarding GOS linkage types was 
observed for GOS fermentation by piglet and human inocula. 
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The project  
The immature gastro-intestinal barrier of the neonate is a health risk factor. The immaturity 
can lead to increased antigen transfer, local inflammatory reactions and impaired 
immunological development of the intestinal microflora. These effects are considered not 
only in terms of immediate disease, but also as factors increasing the chance of chronic 
diseases during the adulthood. Chronic diseases can include auto-immune diseases, 
allergies, asthma and atopic skin disorders as well as inflammatory bowel diseases.  
Compounds that can influence the body response to immunological changes are designated 
as immuno-modulators. Many immuno-modulators have been identified as carbohydrates, 
and the most well studied class of carbohydrates are lactose-based oligosaccharides 
(LBOs). LBOs are present in human breast milk (HMO – human milk oligosaccharides) as 
a highly complex mixture, or they can be enzymatically manufactured, resulting in a 
galacto-oligosaccharide mixture (GOS). 
A multidisciplinary project named ‘Immuno-modulation of oligosaccharides from various 
sources’ was conducted within the Carbohydrate Competence Center program. The project 
focused on the investigation of the chemical structure and function of LBOs, in relation to 
their immunological aspects. This thesis, as part of the project, aimed to study aspects of 
isolation, characterization and in vitro fermentation of LBOs from different sources, such as 
milk from various mammals and manufactured GOS.  
Lactose-based oligosaccharides 
Oligosaccharides are defined as carbohydrates with a degree of polymerization (DP) from 2 
to about 10, according to the IUB-IUPAC nomenclature.1 The main oligosaccharide with 
DP2 in mammalian milk and in manufactured GOS is represented by lactose (53-70 g/L in 
human milk).2, 3 Lactose is an oligosaccharide hydrolysed by intestinal lactase and has been 
described aside from oligosaccharides.4 Therefore, in this PhD thesis, LBO descriptions 
exclude lactose, while they include oligosaccharides with DP2 other than lactose. 
Mammalian milk oligosaccharides  
Mammalian milk oligosaccharides (MMOs) are the third largest component in human milk, 
after lactose and lipids.4 The concentration of MMOs  depends on the milk origin and the 
lactation stage of the mammal: 21-24 g/L and 12-13g/L for human milk oligosaccharides 
(HMOs) in human colostrum and in mature milk, respectively; about 1g/L and 0.05g/L in 
MMOs in cow colostrum and in mature milk, respectively; and 0.25-0.3 g/L MMOs in goat 
mature milk, and about 0.03 g/L in ovine mature milk.5-7 Domestic animal MMOs are 
present overall in 100-1000 fold lower concentrations than HMOs.8  
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In general, MMOs have a lactose unit (Gal(β1-4)Glc) at their reducing end. In bovine, 
equine and caprine milks, lactose or N-acetyllactosamine (Gal(β1-4)GlcNAc) can be found 
as reducing unit.4, 5, 9 Lacto-N-biose (Gal(β1-3)GlcNAc) and N-acetyllactosamine can 
elongate the above described units, forming type I or type II MMOs, respectively (Figure 
1).10 MMOs are elongated by glycosyltransferases present in the mammary gland, forming 
oligosaccharides up to around DP10.4 Monomers that can elongate the MMO structure are 
the neutral sugars galactose, fucose, N-acetylglucosamine and, in domestic animal milk, N-
acetylgalactosamine. Sialic acids, like N-acetyl-neuraminic acid for human milk, and both 
N-acetyl- and N-glycolyl-neuraminic acids for animal milk, can also elongate the MMO 
structure. In case of domestic animal milk, glucose and N-acetylglucosamine substituted 
with one phosphoric group was also reported as part of the MMO structure.4, 11, 12 The core 
oligosaccharide structure of MMOs can be divided into 12 groups as represented in Figure 
1. Classification is based on core structure of MMOs, containing 1-3, 1-4 and 1-6 
linked neutral monomers. These core structures can be elongated by fucose, attached via 
1-2, 1-3,1-4 and/or by N-acetylneuraminic acid, attached via 2-3 and 2-6.4, 13 
The compositions of the MMOs found in human milk and common domestic animal milks 
are summarized in Table 1. Not all MMOs found in human milk are found in domestic 
animal milks and vice-versa. The major HMOs reported are the neutral 2’-fucosyllactose 
(2’-FL), lacto-N-tetraose, fucosyllacto-N-pentaose-I, and lacto-N-difucosylhexaose-II 
(numbers 9, 13, 19, and 26, highlighted in bold in Table 1) next to the acidic 3'-sialyllactose 
(3’-SL), 6'-sialyllactose (6’-SL), sialyllacto-N-tetraose-a, sialyllacto-N-tetraose-b, 
sialyllacto-N-tetraose-c, and disialyllacto-N-tetraose (numbers 33, 34, 44, 45, 46 and 48, 
highlighted in bold in Table 1).4 Interestingly, only 3 of the major HMOs are present in 
domestic animal milk: 2’-FL is present in caprine and porcine milks (number 9, Table 1), 
while 3’-SL and 6’-SL are present in bovine, equine, caprine, ovine and porcine milk. The 
composition of MMOs depends on the milk origin, including animal breed and mammal 
lactation stage.2, 14-17 Some HMOs seem to be present specifically in human milk and not in 
domestic animal milks. Sialylated tetramers (numbers 44-46, Table 1), mono-fucosylated 
pentamers (numbers 19 and 20, Table 1) and mono- or di-fucosylated hexamers (numbers 
25, 26 and 29-31, Table 1) are present in high abundance in human milk, while they were 
not reported for domestic animal milk. 
1 
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Figure 1. Core oligosaccharide structures as found in human milk. Colours indicate dimers presenting 
the same linkage type. Adapted from Haeuw-Fievre et al.13 With Gal = galactose, Glc = glucose and 
GlcNAc = N-acetylglucosamine. 
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HMOs are reported to be highly fucosylated (covering 50-80% of the HMO structures) and 
poorly sialylated (accounting for 10-30% of the HMOs), whereas domestic animal milks 
showed the opposite trend.4, 8 In general, domestic animal milks show a high level of 
sialylation (70, 13, 41, 50, and 62%, for bovine, equine, caprine, ovine and porcine milk, 
respectively, Table 2) and low levels of fucosylation (1-5, 0, 18, 0, and 24% for bovine, 
equine, caprine, ovine and porcine milk, respectively, Table 2) when comparing the number 
of structures reported so far. 4, 8, 16  
Table 2. Overall characteristics of mammalian milk oligosaccharides (MMOs) identified in milk of 6 
mammals. 
 
HMOs = human milk oligosaccharides. With. a = Ref.8; b = Ref. 4; c = Ref.16.  
Another essential difference between human and domestic animal milk, is the type of sialic 
acid present. HMOs exclusively contain N-acetyl-neuraminic acid (Neu5Ac), while 
domestic animal milk oligosaccharides might contain either N-acetyl- or N-glycolyl-
neuraminic acid (Neu5Gc) (e.g. numbers 36 and 39, Table 1).9 The presence of Neu5Gc in 
domestic animal milk is considered an undesired characteristic when this milk would be 
applied in human nutrition, since Neu5Gc-antibodies were found upon several human 
diseases, such as chronic hepatitis and cancer.18, 19 
Galacto-oligosaccharides  
Galacto-oligosaccharides (GOS) are industrially produced from lactose by a β-
galactosidase of microbial or yeast origine.10 The composition of GOS strongly varies with 
enzyme origin and conditions used during GOS production, such as temperature, pH and 
substrate concentration.20 GOS mainly consist of galactose oligomers with a terminal 
reducing glucose, mostly in the range of 2-8 (Table 3).20 Glycosidic linkages that could 
exist between GOS monomeric units are β1-2, β1-3, β1-4 and β1-6, as exemplified in Table 
3. Next to glucose at the reducing end of GOS structures, also non-reducing terminal 
Humana,b Bovinea,c Equinec Caprinec Ovinec Porcinec
Number of MMOs
structures identified >100 22 8 17 6 21
neutral structures identified >47 10 6 10 3 8
sialylated structures identified >44 9 1 7 3 13
phosphorylated structures 0 3 1 0 0 0
Percentage based on MMO number
sialylated  structures 10-30 70 13 41 50 62
fucosylated structures 50-80 1-5 0 18 0 24
structural overlap with HMOs ─ 23 63 41 67 38
Mammalian milk oligosaccharides (MMOs)
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glucose or galactose presenting a 1-1 linkage can be found, accounting for about 7% 
(w/w) of the GOS-DP2. 20, 21  
Table 3. GOS-DP2-4 isomers identified in commercial GOS preparations. 3, 20, 22 
 
DP = degree of polymerization; Gal = galactose; Glc = glucose; Fru = fructose. 
Physiological fate and properties of lactose-based oligosaccharides 
Fermentation 
It has been shown in vitro that GOS resist to acidic stomach conditions and hydrolysis by 
mammalian enzymes.23 Also HMOs have been found to resist in vitro pancreatic and brush 
border enzyme digestion.8 In vivo, more than 90% of dietary GOS and HMOs are reported 
to resist metabolization and to reach the colon.10, 24, 25 In some cases, GOS and HMOs are 
still detectable in fecal samples.10, 24, 25 LBOs are defined prebiotics, since they reach the 
colon and they can influence intestinal microbiota composition resulting in beneficial 
effects for the host.8, 21, 23, 26 Both GOS and HMOs have been shown to be substrates for 
bifidobacteria fermentation, promoting bifidobacteria growth. It was shown that babies fed 
with human milk had higher amounts of bifidobacteria in their intestine, when compared 
with formula (not containing GOS) fed infants.27 In general, a shift towards high numbers 
of bifidobacteria in the large intestine has been reported to be favourable for the host.28 
Being competitive species for both spatial adhesion to the intestinal mucosa and nutrient 
supply, bifidobacteria may give protection against harmful bacteria,.8, 28 Moreover, 
bifidobacteria as diet supplementation decrease symptoms of chronic enterocolitis and 
lymphoid hyperplasia, and lowers the level of blood cholesterol.28 As a consequence of 
STEFANIE THESIS PAGE 11
β-D-Gal-(1<->1)-β-D-Glc 7
β-D-Gal-(1->2)-D-Glc 16
β-D-Gal-(1->3)-D-Glc 26
β-D-Gal-(1->3)-D-Gal 1
β-D-Gal-(1->4)-D-Glc (lactose) 27
β-D-Gal-(1->4)-D-Gal 3
β-D-Gal-(1->4)-D-Fru (lactulose) 5
β-D-Gal-(1->6)-D-Glc (allo-lactose) 15
β-D-G l-(1->4)-β-D-Gal-(1->4)-D-Glc
+ β-D-Gal-(1->4)-β-D-Gal-(1->4)-Fru45
β-D-Gal-(1->4)-β-D-Gal-(1->6)-D-Glc
or β-D-Gal-(1->6)-β-D-Gal-(1->4/6)-D-Glc15
β-D-Gal-(1->4)-β-D-Gal-(1->6)-D-Glc
or β-D-Gal-(1->6)-β-D-Gal-(1->4/6)-D-Glc9
β-D-Gal-(1->4)-β-D-Gal-(1->3)-D-Glc 8
β-D-Gal-(1->6)-[β-D-Gal-(1->2]-D-Glc 5
β-D-Gal-(1->4)-β-D-Gal-(1->2)-D-Glc 9
other 9
DP4 DP3 DP2
Gal(1-3)Gal 
Gal(1-4)Gal 
Gal(1-4)─ Gal(1-2)Glc
Gal(1-4)─ Gal(1-3)Glc
Gal(1-4)─ Gal(1-4)Fru (lactulose)
Gal(1-2)─ Glc(1-1)Gal
Gal(1-4)─ Gal(1-4)─ Glc(1-1)Gal
Gal(1-6)─ Gal(1-4)Glc (lactose)
Gal(1-4)─ Gal(1-4)─ Gal(1-4)Glc (lactose)
[Gal(1-2)]─ Gal(1-6)Glc (allo -lactose)
Gal(1-6)─ Gal(1-4)─ Gal(1-6)Glc (allo -lactose)
Gal(1-4)─ Glc(1-1)─ Gal(4-1)Gal
 GOS-DP2-4 structures
Glycosyl Substituent
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MMOs and GOS fermentation by colonic microbiota, short chain fatty acids are produced. 
Among short chain fatty acids produced, butyrate has been shown to play and important 
role in the intestinal health. It decreases intestinal inflammation, carcinogenesis and 
oxidative stress of the intestine.21, 29, 30 Due to their structural similarities with HMOs, GOS 
can replicate their bifidogenic effect, explaining their role as fortifier in infant formula.21 
Pathogen inhibitor 
LBOs can exert protective functions in the intestine, being soluble ligands for pathogens in 
the receptor-mediated pathogen infection. GOS resemble glyco-conjugate cell surface 
receptors and can prevent colonization of pathogen on the intestinal surface.21 It was shown 
that acidic HMOs can prevent the attachment of Escherichia coli and Helicobacter pylori to 
the intestinal mucosa, while both acidic and fucosylated HMOs can prevent the attachment 
of Campylobacter jeuni, being the main cause of bacterial diarrhoea and infant mortality.31, 
32  
Immunomodulation 
Recent studies suggest that HMOs can directly interact with intestinal cells, leading to host 
protection against bacterial infection.8 3’-Sialyllactose has been reported to decrease in 
vitro gene expression of sialyltransferases, thus reducing sialic acid glycan decoration on 
the cell surface.8, 33 Therefore, adhesion of the pathogenic Escherichia coli, binding a sialic 
acid moiety on the cell surface as first step for infection, was inhibited.33 HMOs are 
suggested to directly act as ligand for specific sugar-receptors present on immuno-cells.34 
Interaction of HMOs with the immuno-system has been shown to have protective functions 
(in vivo), leading to leucocyte (white blood cells) recruitment to inflammation site, 
balanced T helper (Th) 1 to Th2 ratio’s and an decrease of Th2 immuno-response to 
allergens.42 Also GOS have been reported to possibly protect infants from allergic disorders 
during the first five years of their lives.35 Therefore, dietary intervention in early stages of 
life with LBOs can lead to prevention of immunological and allergic diseases in later stages 
of life.34  
Systemic absorption and excretion  
Although it has been demonstrated that major parts of LBOs reach the colon, also a partial 
adsorption of HMOs into the blood circulation (systemic adsorption) has been shown.8 In 
infants, about 1% of both neutral and acidic dietary HMOs have been found present 
systemically.36, 37 It has been shown in vitro that neutral HMOs pass the intestinal cells 
through both para-cellular and receptor-mediated trans-cytosis pathway, while acidic 
HMOs pass the intestinal cells only through para-cellular pathway.38 It was suggested that 
HMOs containing sialic acid and being present systemically, could help brain development, 
General introduction 
11 
 
as dietary-sialic acid has been reported to increase the learning speed and memory abilities 
in piglets.39  
After intestinal absorption, HMOs can be excreted by the urinary system, where they were 
also suggested to have protective functions.18, 40-42 Literature reports on sialylated HMOs as 
protective agents against urinary Escherichia coli infection and cystitis.18, 43 As described 
for HMOs, also GOS have been reported to reach the intestinal tract for more than 90%, 
being possibly in minor part absorbed.21, 26 In vitro study described GOS passage through 
cell line monolayer, depending on their size and structure, indicating their possible 
absorption in vivo.44 
Pig as a model for human intestinal study 
Intestinal fermentation and intestinal microbiota modulation of LBOs have a key role in 
human and animal health.45 Therefore, in vivo and in vitro models have been developed in 
order to study the intestinal fate of LBOs.  
In vivo pig model 
In vivo models can be based on animal and human intervention studies.46 For obvious 
ethical reasons, it is not possible to collect contents from the different gastro-intestinal 
regions of infants, while in vivo animal models provide a valuable alternative for sample 
collection. Mice are small and easy to handle experimental animals. Nevertheless, they 
show differences in bifidobacteria population and eating behaviour compared with 
humans.46 Pig intestinal functions, anatomy and nutritional requirements are comparable 
with those of humans.47 Pigs are considered to be a good model, not only to mimic human 
intestine, but also to mimic immunological intestinal changes.48 Pig models can be used to 
investigate infant pathologies associated with intestinal microbiota, such as diarrhea 
supported by Escherichia coli and rotavirus, necrotising enterocolitis and obesity.47 Pigs as 
well as humans are omnivorous species, with comparable digesta transit times and 
comparable digestive and absorptive processes.47, 49, 50 Both species are colon fermenters 
and their colonic microbiota have analogous compositions.50 Both species present as major 
bacterial groups Firmicutes, Bacteriodes.51 Nevertheless, as for mice, pigs present 
differences in level and type of bifidobacteria when compared with human intestinal 
bifidobacteria population. 47, 52, 53 Moreover, pig has been shown already in the cecum an 
extensive fermentation, while cecal fermentation has been shown to be limited in humans.46 
Overall, it has been stated that pig provide a valuable alternative to human in order to study 
fermentation and metabolization phenomena in different regions of the gastro-intestinal 
tract.46, 47 
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In vitro fermentation model  
Invasive sampling techniques, high costs and ethical reasons are the drawbacks of in vivo 
human and animal trials, which are, therefore, not always feasible. In order to overcome 
these restrictions, in vitro models using human or animal fecal inocula can be used. In vitro 
models are easy to set and may have a high throughput.3, 54, 55 In vitro models can include 
fermentation in 1 batch or in a 3-container system, where the pH can be set in each 
container individually in order to mimic the pH-changes along the gastrointestinal tract.56, 57 
A more complex intestinal model has been described as the TIM-2 (TNO gastro-intestinal 
model) that represents the intestine from stomach untill the colon.58-60 The TIM-2 model 
represent the in vivo physiology better than batch in vitro model, since absorption of small 
molecules such as nutrients, drugs and water is simulated. However, the low throughput 
makes its use still quite expensive, making batch fermentation still a valuable alternative.  
Since the pig digestive system is described to be a suitable in vivo model for the human 
digestion system, studies have been conducted in order to compare fermentation of non-
digestible oligosaccharides by human and by pig inocula in vitro.54, 61 In these studies 
differences in gas, SCFAs production and remaining soluble carbohydrates content were 
highlighted.54 Overall, human microbiota was able to degrade a larger variety of fibers than 
pig microbiota.54, 61 Saccharolytic fermentation stopped earlier during fermentation by pig 
inocula than by human inocula.54, 61 SCFAs production was higher during fermentation by 
human inocula than by pig inocula.54, 61 In these studies, it was suggested that microbiota of 
humans and pigs were adapted to the different types of fibers: humans consumed a large 
variety of fibers, including retrograded starch and pectin, while pigs mainly consumed 
maize-, barley- and wheat- fibers.54, 61 Therefore, differences in in vitro fermentation 
characteristics are expected when using human or pig inocula.  
Analysis of lactose-based oligosaccharides  
LBOs are usually present as complex mixtures. The complexity is caused by the wide 
diversity in composition, size and presence of isomers both in HMOs and in GOS.4, 21 The 
higher the degree of polymerization, the higher the number of isomeric structures that are 
possibly present in the mixture. For these reasons, LBO separation and characterization 
represent a challenge that can be approached with several techniques. 
Liquid chromatography 
Liquid chromatography (LC), such as high-performance anion-exchange chromatography 
(HPAEC) and (ultra) high performance liquid chromatography ((U)HPLC) are often used in 
order to separate LBOs.7, 20, 62-64 For example, hydrophilic interaction liquid 
chromatography, porous graphitized carbon column and C18 columns have been introduced 
for the separation of LBOs.65-67 In order to avoid the occurrence of anomeric peaks in LC 
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analysis of oligosaccharides, labelling techniques were implemented, allowing a good 
separation and at the same time sensitive quantification of oligosaccharides using 
fluorescent detection.68, 69 The labels mostly used are 2-aminopyridine, 2-aminobenzamide 
and 2-aminobenzoic acid, which all reacted through condensation with the reducing end of 
the oligosaccharides.4, 68, 70, 71 The labelling procedures requires conditions (e.g. incubation 
at 65oC for 2h) that are sufficiently mild for most oligosaccharides, however they may 
enhance the release of fucose and sialic acid residues from specific MMO structures.4, 66 
Mass spectrometry 
Mass spectrometry allows LBO characterization and may even allow the complete 
elucidation of (isomeric) MMOs. After separation by chromatographic and/or non-
chromatographic techniques, quantification in mass spectrometry of LBOs is possible with 
the use of selected ion monitoring, multiple reaction monitoring, or standard calibration 
curves.17 Matrix-assisted laser desorption ionization time-of-flight mass spectrometry 
(MALDI-TOF-MS), both in positive and negative ionization mode, has been often use in 
order to characterize LBOs, mainly HMOs.24, 67, 72 GOS are also detectable by MALDI-
TOF-MS resulting in one peak per DP. With MALDI-TOF-TOF-MS, a screening of the 
structures present in MMOs was performed by mass fragmentation analysis and isomeric 
structures of acidic HMOs were elucidated.72 
Non-chromatographic techniques 
Capillary electrophoresis (CE) with laser induced fluorescent detection has been 
successfully used to both characterize and quantify LBOs after oligosaccharide labelling at 
their reducing end.10 Despite high sensitivity and good peak separation and high resolution, 
this technique requires the use of standards for characterization, and it doesn’t allow the 
analysis of non-reducing oligosaccharides, present in minor amounts in GOS.20 CE can be 
coupled to a mass spectrometer (MS) enabling structure identification, independently from 
standards. CE-MS, nevertheless, results in a decreased sensitivity and peak separation and 
resolution.73 Nuclear magnetic resonance, both on proton and carbon, has been successfully 
used to elucidate specific LBOs structures, obtained after chromatographic separation, 
although is limited to relatively pure and concentrated samples.13, 74-76 
Thesis outline 
Human milk oligosaccharides (HMOs) have been reported to be highly beneficial for the 
infants, therefore composition of HMOs has been extensively investigated. Contrarily, milk 
oligosaccharides present in domestic animal milks have been investigated to a lesser extent. 
As demonstrated for HMOs, milk oligosaccharides composition depends on the milk origin 
and on the mammal stage of lactation. Therefore, in this thesis we describe LBO structures 
1 
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and concentrations present in different mammalian milks with emphasis on inter-individual 
variation of milk oligosaccharides. Moreover, nowadays when breastfeeding is not possible, 
dietary supplementation with infant formula fortified with manufactured galacto-
oligosaccharides (GOS) is pursued. GOS intestinal fermentation represent a crucial event 
for their beneficial effects. Therefore, GOS and dietary oligosaccharides fermentation in 
vitro was investigated. In addition, as described from HMO presence in infant blood and 
urine, also GOS and dietary oligosaccharides were expected to be present systemically, 
hypothesizing that they could have the same metabolic fate as HMOs. 
In Chapter 2 equine milk was investigated for its oligosaccharides content. Equine milk 
oligosaccharides (EMOs) were described highlighting their differences in composition 
between breeds as well as per individual. EMOs identified were compared for their 
structural similarities including the bifidogenic-factor with oligosaccharides present in milk 
from human and other domestic animals. 
In Chapter 3 porcine milk was evaluated, describing porcine milk oligosaccharides 
(PMOs) as found in different colostrum and mature milk samples. PMO concentration in 
colostrum, mature milk and in fecal samples from suckling piglets was evaluated.  
The pig intestinal system is considered to be a good model for human intestinal system. In 
Chapter 4, an experiment is described, in which piglets fed for 3 or 26 days on a diet 
enriched with GOS were sacrificed and biological samples (blood and urine) were 
collected. The biological samples were analysed with respect to dietary oligosaccharides 
and GOS presence in blood and urine of piglets, as well as in feces.  
Oligosaccharides were fully consumed/absorbed during the in vivo piglet feeding trial, 
hindering conclusion on individual oligosaccharide utilization by intestinal microbiota. In 
Chapter 5, in vitro fermentation of PMOs and GOS was described using piglet fecal 
inocula. PMO and GOS fermentation was evaluated for individual oligosaccharide 
consumption and organic acid production.  
Finally, the results obtained in the research are discussed in Chapter 6 and their impact on 
future research on LBOs is reflected. 
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Chapter 2 
Comparison of milk oligosaccharides pattern 
in colostrum of different horse breeds 
 
 
 
Abstract 
Colostrum oligosaccharides are known to exhibit prebiotic and immunomodulatory 
properties. Oligosaccharide composition is species-specific, and equine colostrum has been 
reported to contain unique oligosaccharides. Therefore, equine oligosaccharides (EMOs) 
from colostrum from different horse breeds were analyzed by CE-LIF, CE-MSn, HILIC-MSn, 
and exoglycosidase degradation. Sixteen EMOs were characterized and quantified, of which 
half were neutral and half were acidic. EMOs showed about 63% structural overlap with 
human milk oligosaccharides, known for their bioactivity. Seven EMOs were not reported 
before in equine oligosaccharides literature: neutral GalHexc, Gal(1-4)Hex-Hex, 
4’-galactosyllactose, and lactose-N-hexaose, as well as acidic 6’-Sialyl-Hex-Ac-HexNAc, 
sialyllacto-N-tetraose-a, and disialylacto-N-tetraose (isomer not further specified). In all 
colostrum samples, average oligosaccharide concentration ranged from 2.12 to 4.63 g/L; with 
6’and 3’- galactosyllactose, 3’-sialyllactose, and disialyllactose as the most abundant of all 
oligosaccharides (27-59, 16-37, 1-8, and 1-6%, respectively). Differences in presence and in 
abundance of specific EMOs were evident; not only between the four breeds, but also within 
the breed. 
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Introduction 
Mammalian milk and colostrum contain many structures, which are essential for the nutrition 
and health of the suckling neonate. Throughout the past decades, specific oligosaccharides, 
which have been identified in milk and colostrum, have been shown to beneficially affect 
health.4 For example, human milk oligosaccharides (HMOs) carrying the so-called 
bifidogenic factor (Gal(1-3)GlcNAc) have been illustrated to enhance the growth of 
bifidobacteria in the intestine of neonates.5 When bifidobacteria selectively ferment HMOs, 
they produce organic acids, leading to a pH decrease in the intestine. The lowered pH in the 
intestine creates a less favorable environment for the growth of the pathogens and stimulates 
the production of mucin which in turn, enhance the host’s resistance to infections.6 The 
production of SCFA also leads to a stimulation of the immune system through a direct 
interaction with the immune cells of the intestine.6, 7 Moreover, increasing evidence has come 
forward to demonstrate direct immunomodulatory properties of oligosaccharides derived 
from milk and colostrum. Some properties could derive from interaction with specific 
receptors on intestinal epithelial cells and immune cells, such as carbohydrate receptors and 
Toll-like receptors.7-9 In addition, milk oligosaccharides serve as soluble ligands for 
pathogens, preventing viral, and bacterial attachment to the intestinal mucosa.8 The core 
structure of mammalian milk oligosaccharides (MMOs) is, in most cases, a lactose unit 
(Gal(β1-4)Glc) at the reducing end. However, in cow’s, horse’s and goat’s milk, N-
acetyllactosamine (Gal(β1-4)GlcNAc) is also found at the reducing end instead of the lactose 
unit.1, 10 Starting from these disaccharides, glycosyltransferases can elongate the core 
structure with neutral and charged sugars. The neutral sugars that can be attached to the core 
structure are D-galactose (Gal), L-fucose (Fuc), N-acetylglucosamine (GlcNAc) and, with 
the exception of HMOs, also N-acetylgalactosamine (GalNAc).10 The charged sugars that 
can decorate the core structure are sialic acids, both N-acetyl- and N-glycolyl-neuraminic 
acids, and glucose or N-acetylglucosamine substituted with one phosphoric group (e.g., in 
milk oligosaccharides of horses and cattle).1, 10, 11 Depending on the linkage present in their 
chains, the MMOs are divided into two groups: Type I group contains Gal(β1-3)GlcNAc, 
and Type II group contains Gal(β1-4)GlcNAc.12 The reported mature-milk oligosaccharide 
concentration is 12-13 g/L for human milk and approximately 0.05 g/L for cow’s milk.1, 13 
The oligosaccharide concentration in colostrum is higher than the concentration in mature 
milk: 24 g/L in human colostrum and more than 1 g/L in cattle’s colostrum.10, 14 So far, 43 
equine milk oligosaccharides (EMOs) have been reported of which 31 are neutral and 12 are 
acidic.1, 10, 15 Compared to the HMOs, the EMOs have been reported to have a higher degree 
of sialylation (20-30% and 60%, respectively)13 and a lower degree of fucosylation (70% and 
5%, respectively).13 The previously documented EMOs showed a 17% overlap with 
oligosaccharides present in human milk. Although not reported so far, the presence and 
relative abundance of individual EMOs may vary between individual animal breeds, 
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comparable to the variations in HMOs in different human populations.16-18 This study focuses 
on the analysis of EMOs in colostrum samples of four different horse breeds: Dutch 
Warmblood horse, Shetland pony, Crossbred Arabian/New Forest pony and Friesian horse. 
After isolation from the colostrum samples, the EMOs were identified and quantified, 
highlighting the inter-breed (EMOs for the different horse breeds) and the intra-breed (EMOs 
for the same breed) variations.  
Materials and methods 
Materials  
Colostrum samples of horses belonging to four different breeds were obtained from private 
Dutch owners with consent. Five colostrum samples were available for the Crossbred 
Arabian/New Forest pony (Nederlands Rijpaarden and Pony Stamboek), four colostrum 
samples were available for the Dutch Warmblood horse (Royal Warmblood Studbook of the 
Netherlands), two colostrum samples were available for the Friesian horse, and one 
colostrum sample was available for the Shetland pony. Each colostrum was collected within 
12 hours postpartum and frozen (-20o C) until use. The standards 3’-, and 6’-sialyllactose, 3’-
, and 6’-sialyl-N-acetyllactosamine, lacto-N-tetraose, sialyllacto-N-tetraose-a, and lacto-N-
hexaose were purchased from Dextra Laboratories (Reading, UK). The standards 3’-, 4’- 
and 6’- galactosyllactose, lacto-N-tetraose, and lacto-N-neotetraose were bought from 
Carbosynth (Compton, UK). The labelling of the oligosaccharides was accomplished using 
the Carbohydrate Labelling & Analysis Kit (Beckman Coulter, Fullerton, CA, USA). All 
other chemicals used were of analytical grade. Millipore water (Millipore, Darmstadt, 
Germany) was referred to as water in the text. 
Extraction of equine colostral sugars 
The Dutch Warmblood colostrum samples were available in larger quantities than those of 
other breeds. Therefore, a mixture of the Dutch Warmblood colostrum samples was used to 
optimize the extraction method and to obtain enough material to be loaded in the preparative 
Size Exclusion Chromatography. Specifically, 1.25 mL of each colostrum sample was pooled 
together and mixed with a vortex for 2 minutes. After method optimization, EMOs were 
extracted from 1mL of the 12 individual colostrum samples. The optimized sugar extraction 
from the colostrum samples was performed by modification of the method of Nakamura et 
al.15 Briefly, colostrum (5 mL) was treated with 4 volumes of chloroform. After two hours 
head over tail mixing, the sample was centrifuged (5000 x g, 30 min, 5 oC) and the supernatant 
was treated with 2 volumes of methanol. After the same mixing and centrifugation procedure, 
the methanol-water solution was concentrated by vacuum evaporation. The remaining water 
solution was freeze-dried.  
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Purification and fractionation of EMOs 
Size Exclusion Chromatography (SEC) was used to remove lactose from the extracted 
carbohydrates of the pooled Dutch Warmblood colostrum, in order to obtain pools containing 
EMOs with difference degrees of polymerization (DP). In total four pools were obtained and 
they were analyzed for the characterization of the EMOs. The fractionation was carried out 
at 35 oC on three Superdex 30 Hiload 26/60 preparative grade columns (GE Healthcare, 
Pittsburgh, PA, USA) connected in series on an AKTA Purifier (GE Healthcare). After 
manual injection, the EMOs (200 mg) were eluted with water containing 0.5% (v/v) EtOH 
and collected in 9 mL fractions. The fractions were pooled as follows: pool 1: 290- 492 mL, 
pool 2: 493- 688 mL, pool 3: 689 – 730 mL, and pool 4: 731- 758 mL. Using water solution 
as eluent, charged oligosaccharides were excluded from the column material and were eluted 
first. Neutral oligosaccharides were instead fractionated based on their size. Lactose and 
monomers were the last to be eluted and were excluded from further analysis. The neutral 
oligosaccharides were pooled according to the retention times shown by a mixture of neutral 
galacto-oligosaccharides (DP from 1 to 6) (Vivinal® GOS syrup) (FrieslandCampina Domo, 
Borculo, The Netherlands), which was considered a reference for its retention time. After 
freeze drying, the resulting powders were rehydrated with 1mL of water prior to analysis. 
Solid Phase Extraction (SPE) was used to reduce the lactose content from the 12 individual 
colostrum samples. The extracted carbohydrates (1 mg) were solubilized in 1mL of water 
and loaded onto activated graphitized carbon cartridge (150 mg bed weight, 4 mL tube size; 
Grace, Deerfield, IL, USA). Elution with water (1.5 mL) was used to remove salts and 2% 
 (v/v) acetonitrile (ACN) (1.5 mL) was used in order to elute monomers and lactose. The 
EMOs, still bound to the graphitized carbon cartridge, were recovered with 1.5 mL of 40/60% 
 (v/v) ACN/water solution containing 0.05% (v/v) trifluoroacetic acid. The obtained EMOs 
were dried overnight under a stream of nitrogen and subsequently solubilized in 0.5mL of 
water.  
Capillary electrophoresis with laser induced fluorescent and mass spectrometry 
detection  
The EMOs fractionated either by SEC or SPE were labelled with a fluorescent label (9-
aminopyrene-1,4,6-trisulfonate, APTS) for their analysis by capillary electrophoresis (CE) 
with laser induced fluorescence (LIF) detection as reported previously with minor 
modifications.19 Briefly, 100 μL of sample containing 5 nmol of xylose, as internal standard, 
was dried and labelled with APTS. Ten nmol of each oligosaccharide standard, containing 5 
nmol of xylose, was labelled with the APTS and run together with the EMOs samples. The 
labelled samples were diluted 40 times before the analysis. The experiment was performed 
using a ProteomeLab PA 800 system (Beckman Coulter), equipped with a LIF detector 
(Beckman Coulter). During the run, the sample was loaded hydrodynamically (7 s at 0.5 psi) 
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into a polyvinyl alcohol (NCHO) coated capillary (50 μm x 50.2 cm (Beckman Coulter). 
Resultant peaks were integrated manually using Chromeleon software 6.8 (Dionex, 
Sunnyvale, CA, USA). In the CE technique, the oligosaccharides are linked in a molar ratio 
of 1:1 with the fluorescent, negatively-charged label (APTS). The resulting migration times 
of the linked oligosaccharides depend on their size and on their net charge. The SEC-
fractionated, labelled EMOs were also analyzed for their masses by the PA 800 plus system 
(Beckman Coulter) coupled to a Velos Pro mass spectrometer (LTQ Velos Pro ion trap MS, 
Thermo Scientific, Waltham, MA, USA), after 20 times dilution. The CE-MSn experiment 
conditions were performed as reported elsewhere. 20 
HILIC-ESI-MSn  
The EMOs pools, derived from SEC, were also analyzed through hydrophilic interaction 
liquid chromatography (HILIC) with mass spectrometry detection (MSn) as described 
elsewhere 21 with some minor modifications. Briefly, an Accela UHPLC system (Thermo 
Scientific) coupled to a mass spectometer (LTQ Velos Pro ion trap MS, Thermo Scientific) 
was used. The chromatographic separation was performed on an Acquity HILIC BEH Amide 
column (1.7 μm, 2.1 mm × 150 mm) combined with a Van Guard precolumn (1.7 μm, 2.1 
mm × 5 mm; Waters Corporation, Milford, MA, USA). The acquisition time was 72 min and 
the eluents had a flow rate of 600 μL/min. The injection volume was 5L. The composition 
of the three mobile phases were (A) water with 1% (v/v) ACN, (B) 100% (v/v) ACN and (C) 
200 mM ammonium formate (pH 3.0). The elution program was performed as follows: 2 min 
isocratic 80% B; 58 min linear gradient from 80% to 30% B; followed by 12 min of column 
washing with a linear gradient from 30% to 20% B and column re-equilibration form 20 to 
80% B. The eluent C was kept at 5% during the elution. 
Exoglycosidase degradation 
To determine the linkage type of the sialic acid decorating the EMOs, two types of sialidases 
were used: Sialidase S and Sialidase T (ProZyme, Hayward, CA, USA). Sialidase S is 
specific for the 2-3 linked neuraminic acid, while Sialidase T splits 2-3 and 2-6 linked 
neuraminic acid. For the structural analysis of the neutral EMOs Glyco(1-3)galactosidase, 
Glyco(1-4)galactosidase, Glyco(1-4,6)galactosidase and Glyco-N-acetylhexosaminidase 
(ProZyme) were used. All reactions were performed as suggested by the manufacturer. After 
the enzyme degradation at 37 oC overnight, the solutions were centrifuged (5000 x g, 5 min, 
25 oC) and the supernatants were analyzed by HILIC-MSn. 
Quantification of the EMOs 
In CE-LIF the quantification of the oligosaccharides was enabled by the use of an internal 
standard and by a 1:1 stoichiometry between the oligosaccharide and the APTS molecule. A 
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linear correlation between concentration and CE-LIF peak area has been shown.19 CE-LIF 
peak areas were converted to the corresponding EMOs nanomoles and their concentrations 
in the colostrum samples (g/L). The samples were run in duplicate and the quantification was 
validated with the help of labelled neutral and acidic oligosaccharides standards. The 
quantification of 3’-sialyl-N-acetyllactosamine (3’-SLN) and Gal(1-4)Hex-Hex, annotated 
by HILIC-MSn and not assigned in the CE-LIF electropherograms, was performed with 
HILIC-MSn. A calibration curve was made based on the peak areas in mass spectrometry of 
the 3’-SLN, and 4’-galactosyllactose (4’-GL) standards, respectively. The curves fitting 
the 3’-SLN and 4’-GL standards had a linear correlation with R2 of 0.997 and 0.998, 
respectively. 
Results and discussion 
Structural characterization of the equine milk oligosaccharides 
In order to elucidate the structure of the EMOs, a colostrum mixture was prepared using 
Dutch Warmblood colostrum. After sugar extraction, part of the oligosaccharides was 
fractionated using Size Exclusion Chromatography (SEC). A lactose-free EMO mixture was 
obtained pooling part of the SEC fractions. Lactose-free EMO mixture and four SEC pools 
obtained were labelled with the fluorescent dye APTS and subsequently analyzed by CE-LIF 
and CE-MSn. In Figure 1, CE electropherograms of labelled lactose-free EMO mixture and 
SEC pools are shown. The migration times of labelled EMOs were compared with available 
standards and with HMO elution patterns, that have been described in literature.22 In total, 
twenty-four peaks were counted of which eleven peaks were annotated (numbers 2-14, Figure 
1). Together with remaining lactose after SEC (symbol #, Figure 1), the annotation of five 
oligosaccharides was confirmed by CE-MSn analysis. Acidic oligosaccharides were the first 
eluted from the SEC columns and they were mainly pooled in pool 1. Pool 2 contained 
sialyllactose together with neutral pentamer and hexamer oligosaccharides. Pools 3 and 4 
contained neutral tetramer and trimer, respectively. In the CE-MS2, the APTS-labelled 
oligosaccharides showed a specific fragmentation behavior due to the fluorescent molecule 
attached at their reducing end and a multiple charge state in their fragments spectrum. One 
example of CE-MSn identification is given for lacto-N-novo-pentaose I, previously identified 
in equine milk, and shown in Figure 2.1, 3 APTS-lacto-N-novo-pentaose I loses one terminal 
galactose yielding a APTS-tetramer fragment, with m/z 573 and m/z 382, having charge 
states of -2 and -3, respectively. 
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Figure 1. CE-LIF electropherograms of lactose-free EMO mixture and the EMO SEC pools1-4. *: 
Internal standard xylose, #: Lactose, 1-14: identified peaks as named in Table 1. 
The APTS-tetramer fragment loses a terminal galactose producing the fragment GlcNAc-
Gal-Glc-APTS with m/z 492 and 328, having charge states -2 and -3, respectively. The 
GlcNAc-Gal-Glc-APTS subsequently forms APTS-lactose, with m/z 391, having charge 
state -2, via the loss of the terminal N-acetyl-glucosamine. From the fragmentation of the 
APTS-lactose, a molecule of APTS-glucose was formed, with m/z 310, having charge state 
-2. In order to enhance the characterization of the EMOs, the mass analysis was also 
performed with HILIC-MSn with non-labelled oligosaccharides obtained after SEC 
fractionations. With this technique five more EMOs were annotated. All molecules found 
had a charge state of -1. One example for HILIC-MSn identification of 3'-sialyl-N-
acetyllactosamine (3’-SLN) is shown in Figure 3. Two peaks are highlighted for the sialyl-
N-acetyllactosamine (Figure 3a).  
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The highest peak refers to 3’-SLN, while the lowest peak refers to 6’-SLN. Each of the 
molecules were found as a double peak. It is hypothesized that the double peaks correspond 
to the  conformation of the reducing end.23 The MS2 fragmentation of the 3’-SLN was 
compared with existing literature and with MS2 fragmentation of available standard.24 
 
 
Figure 2. Selected base peak for the lacto-N-novo-pentaose-I (LNnP-I) in CE-MSn as present in lactose-
free EMO mixture (a). Corresponding MS2 fragmentation patterns and structural composition of LNnP-
I (b). m/z 436 precursor ion in CE-MSn. [-2], [-3]: charge state of the molecules formed after 
fragmentation, APTS: 9-aminopyrene-1,4,6-trisulfonate. 
The 3’-SLN loses water (Figure 3b), forming thereby the fragment with m/z 655. A 
characteristic intra-ring fragmentation of the molecule leads to the formation of the fragment 
with m/z 572. The fragment with the highest intensity refers to the N-acetylneuraminic acid, 
with m/z 290. For four milk oligosaccharides enzymatic degradation was necessary to 
determine their linkages. The neutral dimer Gal Hexc and the trimer Gal(1-
4)Hex-Hex could be characterized only by using Glyco-galactosidases specific for 1-3, 1-4 
and 1-4, 6 linkages, in addition using the Glyco-N-acetylhexosaminidase. The acidic 6’-
sialyl-Hex[Ac]-HexNAc and 3’-sialyllacto-N-tetraose a (LSTa), could be characterized only 
by using Sialidase S (specific for the 2-3 linked N-acetylneuraminic acid), Sialidase T 
(specific for 2-3 and 6 linked N-acetylneuraminic acid) and Glyco-N-
acetylhexosaminidase. After their enzyme degradation, the samples were analyzed by 
HILIC-MSn. As example, Figure 4 illustrates the enzymatic degradation of 
GalHexc and LSTa prior to analysis by HILIC-MSn. The GalHexc was 
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found as double peak (Figure 4a), as consequence of  conformation of the reducing end. 
Using the enzymes tested, GalHexc was digested by Glyco(1-4)galactosidase 
(Figure 4b), while neither Glyco(1-3)galactosidase nor Glyco-N-acetylhexosaminidase 
showed any activity, indicating the presence of a 1-4 linked, terminal galactose.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Selected base peak for the 3'-sialyl-N-acetyllactosamine (3’-SLN) in HILIC-MSn as present 
in lactose-free EMO mixture (a). Corresponding MS2 fragmentation patterns and structural composition 
of 3’-SLN as found in the lactose-free EMO mixture (b). m/z 673 precursor ion in HILIC-MSn. [-1]: 
charge state of molecules. 
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The LST molecule, as found in the mare colostrum samples, was digested by Sialidase S 
(Figure 4f), proving the presence of a terminal N-acetylneuraminic acid2-3 linked. 
Moreover, the identification of LST-a was confirmed by its migration time in CE, similar to 
commercially available LST-a standard (Table S1, supporting information).  
 
Figure 4. Selected base peak for the Gal(1-4)HexNAc in HILIC- MSn (a) as present in lactose-free 
EMO mixture. Corresponding base peak after degradation by Glyco-galactosidases specific for1-4 
linkage (b), by Glyco-galactosidases specific for1-3 linkage (c), by GlycoN-acetylhexosaminidase 
(d). Selected base peak for the 3’-sialyllacto-N-tetraose-a (LSTa) in HILIC- MSn as present in lactose-
free EMO mixture (e). Corresponding base peak after degradation by Sialidase S specific for the 2-3 
linkage (f). m/z 382 precursor ion for Gal(1-4)HexNAc in HILIC-MSn; m/z 998 precursor ion for 
LSTa in HILIC-MSn. 
Through the combination of CE and HILIC mass analysis and enzyme degradation of the 
SEC pools, it was possible to identify 16 EMOs. All identified EMOs are listed in Table 1, 
and an overview of methods used in order to characterize them (CE migration time, mass 
over charge values, and retention times in CE-MSn, and HILIC-MSn, and enzymes) are 
described in supporting information (Table S1). Comparing the outcomes of this study with 
previous data, seven EMOs were not reported previously, and were presented in Table 1 in 
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e
Gal(1-4)NAcHex
m/z 382
c)
b)
a)
d)
0 3.00 6.00 9.00
0
50
100
0
50
100
0
50
100
0
50
100
Time (min)
LST a
m/z 998
13.0 15.0 17.0
Time (min)
0
50
100
f)
0
50
100
e)
Equine milk oligosaccharides 
33 
bold: the neutral oligosaccharides GalHexc, Gal(1-4)Hex-Hex, 4’-
galactosyllactose, and lactose-N-hexaose, as well as the acidic oligosaccharides 6’-sialyl-
Hex-Ac-HexNAc, LST-a, and disialylacto-N-tetraose (isomer not further specified).1, 10 Full 
identification was possible for six of the novel EMOs, while partial identification was 
possible for three of the novel EMOs. For 6’-sialyl-Hex-Ac-HexNAc, the presence of an 
additional acetyl group (Ac) was confirmed by mass fragmentation. An additional acetyl 
group linked to acidic milk oligosaccharides has previously been reported in equine 
colostrum.1 The additional acetyl group was reported to be linked to the sialic acid group, 
while in our study it was found to be linked to the hexose moiety.  
Comparison of the equine milk oligosaccharides per breed 
After annotation of the EMOs, peaks in the CE-LIF electropherogram of the lactose-free 
EMO mixture were assigned. The peaks assigned were used as a reference for the 
identification of EMOs in the CE profiles of the 12 colostrum samples of the four horse 
breeds. In Figure 5, the EMO profiles of the four breeds are shown, including the peak 
assignments. The CE-LIF electropherograms of the labelled EMOs showed high 
reproducibility and high peak resolution. 
Inter-breed EMOs comparison 
The comparison of the EMO profiles for the four breeds (A, B, C and D in Figure 5) reveals 
that the presence and relative abundance of the different oligosaccharides varied depending 
on the breed. Quantification was carried out after manual integration of CE-LIF peaks area. 
For two compounds, Gal(1-4)Hex-Hex and 3'-sialyl-N-acetyllactosamine, the assignment 
in the CE-LIF EMO profiles was not possible. For these two molecules the quantification 
was obtained with HILIC-MSn. The total concentrations of EMOs varied between the 
different colostrum samples: 4.63 g/L for the Shetland pony, 1.81-6.71 g/L for the Crossbred 
Arabian/New Forest ponies, 1.42-2.75 for the Dutch Warmblood horses, and 1.76-2.48 g/L 
for the Friesian horses (Table 1). Oligosaccharide concentrations found in this study are 
higher than concentrations found in cow colostrum (about 1 g/L).1 For other animals, the 
oligosaccharide concentration has only been reported for mature milks with levels (0.02 to 
0.25 g/L), as expected, lower than the values obtained in this study for equine colostrum.25 
Although a large variation in the total concentration of EMOs was observed, it was noticed 
that the ponies’ colostrum samples contained the highest concentration of EMOs, followed 
by the Dutch Warmblood horses’ and the Friesian horses’ colostrum samples.  Twelve out of 
the 16 EMOs were present in all colostrum samples. Gal(1-4)Hex-Hex and 3'-sialyl-N-
acetyllactosamine were absent in the Friesian horses’ colostrum samples, 4'-
galactosyllactose was absent in the Crossbred ponies’ colostrum samples, and 6'-sialyl-N-
acetyllactosamine was absent in the Dutch Warmblood horses’ colostrum samples (Table 1). 
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In all breeds, the most abundant oligosaccharides were 3'-galactosyllactose, 6'-
galactosyllactose, 3'-sialyllactose, and disialyllactose (numbers 2, 4, 9 and 12 in Table 1). 
 
Figure 5. CE-LIF electropherograms of APTS-derivatised oligosaccharides for the four breeds. A: 
Dutch Warmblood horse; B: Crossbred Arabian/New Forest pony; C: Shetland Pony; D: Friesian horse. 
*: Internal standard xylose, #: Lactose, 1-14: identified peaks as named in Table 1.  
The highest concentrations of '-galactosyllactose, 3'-sialyllactose, and disialyllactose 
were found in the colostrum sample of the Shetland pony (concentrations of 1.91 g/L, 1.73 
g/L, and 0.23 g/L, respectively). These values for EMOs present in Shetland pony colostrum 
are only an indication, since only one colostrum sample was available for the analysis. The 
highest concentration of the 3'-galactosyllactose was found in the colostrum samples of the 
Crossedbred ponies, with an average concentration of 0.14 g/L. In profiles A1, and B1-5 
(Figure 5) high concentrations of non-characterized EMOs, migrating at 5.6 and 6.2 min., 
were observed. From the CE migration time it could be suggested that these are neutral 
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trimers and pentamers, respectively. The unidentified peaks with a retention time of 6.5, and 
6.6 min (Figure 5), suggesting acidic or neutral hexamers, were present in all colostrum 
samples. The oligosaccharide with the lowest observed concentration in all colostrum 
samples was 3'-sialyl-N-acetyllactosamine with an average concentration of 0.02 g/L.  
Intra-breed comparison of EMOs 
Evaluating the EMOs profiles within the same breed, differences were also noticed. 
Specifically, for the Dutch Warmblood profiles, 6'-galactosyllactose and 3'-sialylactose 
(numbers 2 and 9 in Table 1) were the most abundant oligosaccharides and their 
concentrations varied by a factor 3.2 and 4, respectively. 6'-galactosyllactose was present 
with a concentration of 0.65-2.08 g/L, while 3'-sialylactose with was present with a 
concentration of 0.29-1.16 g/L. Looking at the overall electropherograms, the Crossbred 
ponies’ colostrum samples contained the same EMOs structures, although they highly varied 
in concentration. 4'-Galactosyllactose, however, was not detected in three colostrum 
samples (B3-5, Table 1). In the Crossbred ponies’ colostrum samples, similarly to the Dutch 
Warmblood horses’ colostrum samples, the most abundant oligosaccharides were the 6'-
galactosyllactose and the 3'-sialylactose. The 6'-galactosyllactose was present in a 
concentration of 0.55-3.15 g/L, while the 3'-sialylactose with was present in a concentration 
of 0.38-1.75 g/L, exhibiting a 5.7 and a 4.6 factor, respectively. Intra-breed analysis showed 
relatively high variation in EMOs concentration (Table 1). Most probably the variation in 
EMOs concentration could be dependent on the intrinsic variation in composition and in 
quality of colostrum among individuals, as shown before for cow milk and colostrum.26, 27 
Profile of equine milk oligosaccharide structures in comparison with those in milk 
of other mammals 
Ten out of the 16 EMOs found in this study were also found in milk samples from other 
domestic animals (Table 2). So far, 6'- and 3'- galactosyllactose, 3'-sialylactose, and 3'-
sialyl-N-acetyllactosamine have been found in bovine, caprine, and ovine milk, while 6'-
sialyllactose and disialyllactose have been found both in bovine and caprine milk.10, 28 Lacto-
N-hexaose was characteristic for caprine milk, while 4'-galactosyllactose, lacto-N-novo-
pentaose I, and 6'-sialyl-N-acetyllactosamine were present in bovine milk.10, 11, 28 Ten out of 
16 milk oligosaccharide structures present in equine colostrum were previously reported to 
be present in human milk: the neutral trimers, tetramer, and hexamer, and the acidic 3’-, 6’-
sialyllactose, tetramer, pentamer, and hexamer.12, 22 The presence of milk oligosaccharides 
carrying the bifidogenic factor (Gal(1-3)GlcNAc) (number 6, 7, and 13 in Table 1) and the 
presence of eight EMOs decorated with sialic acids suggest bioactivity of the EMOs, such as 
being bifidogenic and soluble ligands for intestinal pathogens.5, 29-32 In this study, EMOs 
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decorated with N-glycolylneuraminic acid (Neu5Gc) were not detected, while they were 
reported to count for less than 1% in previous study.1 
Table 2. EMOs found in the Dutch Warmblood horses’ colostrum and their presence in other 
mammalian milk samples. 
 
X = present; ─ = not present, * = isomer not further specified. Structures in bold: oligosaccharides 
novel for the equine milk literature.1-3 a = Ref. 1, 3, 12; b = Ref. 11, 12; c = Ref 12, 28; d = Ref. 12, 28; e = Ref. 
12, 22. 
The presence of Neu5Gc linked to milk oligosaccharides is not rare in oligosaccharides 
derived from domestic animals. For example, such oligosaccharides account for about 6% of 
the oligosaccharides in cows’ colostrum.1 On the contrary, milk oligosaccharides decorated 
with Neu5Gc are absent in human colostrum, which is considered as beneficial since blood 
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DEGREE OF 
POLYMERIZATION 
EMO structures 
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a
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b
 
 
SHEEP
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e
 
 
NEUTRAL EQUINE MILK OLIGOSACCHARIDES 
    
DIMER Gal(1-4)HexNAc ─ ─ ─ ─ 
TRIMER 
Gal(1-4)Hex-Hex ─ ─ ─ ─ 
6'-Galactosyllactose X X X X 
'-Galactosyllactose X ─ ─ X 
3'-Galactosyllactose X X X X 
TETRAMER Lacto-N-neotetraose ─ ─ ─ X 
PENTAMER Lacto-N-novo-pentaose I X ─ ─ ─ 
HEXAMER Lacto-N-hexaose  ─ ─ X X 
ACIDIC EQUINE MILK OLIGOSACCHARIDES 
    
TRIMER 
6'-Sialyl-N-
acetyllactosamine 
X ─ ─ ─ 
3'-Sialyl-N-
acetyllactosamine 
X X X ─ 
3'-Sialylactose X X X X 
6'-Sialyllactose X ─ X X 
6’-Sialyl-Hex-Ac-HexNAc ─ ─ ─ ─ 
TETRAMER Disialyllactose X ─ X X 
PENTAMER Sialyllacto-N-tetraose-a ─ ─ ─ X 
HEXAMER Disialyllacto-N-tetraose* ─ ─ ─ X 
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antibodies against Neu5Gc are present in several diseases such as acute and chronic hepatitis, 
hyperacute transplant rejection, and cancer. 12, 32-34  
In summary, oligosaccharide profile of colostrum from horses showed significant differences 
between breeds as well as per individual. EMOs identified showed quite some overlap with 
oligosaccharides present in milk from human and other mammals, although also horse 
specific structures were identified. The presence of EMOs carrying the bifidogenic factor 
and/or the N-acetylneuraminic acid, together with low concentrations of EMOs with N-
glycolylneuraminic acid, could make equine colostrum a good source for further research 
into in vitro bioactive effects of milk oligosaccharides.  
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Chapter 3 
Milk oligosaccharide variation in porcine milk 
and their fermentation in piglet intestine  
 
 
Abstract  
Porcine milk oligosaccharides (PMOs) were analyzed in six colostrum and two milk 
samples from Dutch Landrace sows. In total, 35 PMOs were recognized of which 13 were 
novel for the PMO literature: neutral HexNAc-Hex, 4'-galactosyllactose, putative 
GalNAc(-3)Gal(-4)Glc, lacto-N-fucopentaose-II, lacto-N-tetraose, galactose 
substituted lacto-N-neohexaose, lacto-N-hexaose and difucosyl-lacto-N-hexaose, and acidic 
Neu5Ac(2-6)GlcNAc1-3)Gal1-4)Glc, sialyllacto-N-tetraose-a and -b, Neu5Ac2-Hex3 
and sialyllacto-N-fucopentaose-II. PMOs were analyzed using capillary electrophoresis 
with laser induced florescence detection or mass spectrometry and using liquid 
chromatography with mass spectrometry. Inter-individual variation regarding PMO 
presence and concentration was observed between porcine milks. Moreover, during 1 week 
lactation period, a 43% decrease of the major PMOs was found. In particular, Gal(1-
3)Gal(1-4)Glc, 3'-sialyllactose and sialyllacto-N-hexaose (isomer not further specified) 
decreased. Some other PMOs such as 3'-galactosyllactose, lacto-N-neotetraose and sialyl-
lacto-N-tetraose-a increased in concentration. PMOs were also monitored in fecal samples 
of suckling piglets. In feces of 1-2 days old piglets few intact PMOs were found, indicating 
considerable PMO fermentation at early stage of life. 
 
Submitted for publication as: 
Difilippo, E.; Pan P.; Logtenberg, M.; Willems, H.A.M; Braber, S.; Fink-Gremmels, J.; 
Schols, H.A.; Gruppen, H., Milk oligosaccharide variation in porcine milk and their 
fermentation in piglet intestine.  
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Introduction 
Milk is essential for newborns as it contains proteins, minerals, vitamins, lipids, lactose and 
oligosaccharides.1, 2 Mammalian milk oligosaccharides (MMOs), being fermentable 
substrates for the intestinal microbiota, enhance the growth of bifidobacteria in the 
intestine.3-5 Moreover, intestinal fermentation of MMOs leads to the production of short 
chain fatty acids (SCFAs) including butyric acid. The latter has been shown to be an 
important energy source for colonocytes and a possible inhibitor of inflammation and 
carcinogenesis in the intestine.6 MMOs are also reported to protect the intestinal epithelium 
against pathogens.2 Being soluble ligands for intestinal pathogens, MMOs avoid pathogen-
attachment to the intestinal mucosa, thereby preventing infection.2, 4, 5 In addition, 3’-
sialyllactose, one of the most abundant acidic oligosaccharides in many mammal milks, has 
been suggested to decrease glycosyltransferase expression in epithelial cells.1, 5, 7, 8 This 
down-regulation reduces the presence of sialic acid, fucose and galactose at the epithelial 
cell surface, potentially inhibiting pathogen adhesion to the cells.1, 5, 7, 8 Effects on the host 
immuno-system have been also suggested for MMOs. Both in vitro and ex vivo studies 
have demonstrated that MMOs decrease pathogen-associated inflammation.9, 10 Sialic acid 
levels in infant brains correlate with dietary sialic acids consumption.11, 12 It has been 
suggested that sialylated oligosaccharides increase learning speed and memory ability, as 
concluded from an in vivo piglet trial.13, 14 The development of pig brain shows similarities 
with that of human infants, suggesting dietary sialic acid contribution to cognitive 
development of infants.14  Because of the multiple beneficial functions of MMOs, there is 
increasing interest in the characterization of MMOs and in their fate in the intestinal tract.2, 
4, 5 MMO concentration varies among species and lactation period.1, 15, 16 Commonly, 
colostrum contains the highest concentration of oligosaccharides, while mature milk 
contains a decreased concentration of MMOs.1, 15, 16 In human milk, oligosaccharide 
concentration decrease from about 24 to 12 g/L, while in bovine milk, oligosaccharides 
concentration decreased from about 1 to 0.05 g/L, for colostrum and mature milk, 
respectively.1, 15, 17At the reducing end of the molecular structure of MMOs, either lactose 
or of N-actelyllactosamine is present. To these moieties, monosaccharides such as 
galactose, N-acetyl-glucosamine, N-acetyl-galactosamine, fucose and sialic acids can be 
attached.17 Addition of sialic acids to MMOs occurs via 2-3 or 2-6 linkages, while 
addition of fucose occurs via 1-2, 1-3, or 1-4 linkages, resulting in a wide variety of 
acidic and neutral oligosaccharides.17 Moreover, sulfated and phosphorylated MMOs are 
reported to be present in domestic animal’s milks.1, 7, 17 
Bio-activity of MMOs is suggested to be closely related to their structure.5 Oligosaccharide 
composition in milk varies due to diet, health, lactation stage, both in human and domestic 
animals.2, 5, 17, 19, 20 Recently, 39 porcine milk oligosaccharides (PMOs) have been 
identified, of which 19 are neutral and 20 acidic.7 Of the PMOs reported, 11 are also found 
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in human colostrum. Differently from human milk oligosaccharides, PMOs present a quite 
lower proportion of fucosylated structures: 5% and 70% for porcine and human milk 
oligosaccharides, respectively.1, 7, 15 Although PMOs were described 5, 7, 17 little is known 
about PMO variation per sow and per lactation period.  
In this study, the oligosaccharide content in porcine colostrum and mature milk in Dutch 
Landrace sows were investigated, with attention to PMO inter-individual variation and 
changes in PMO abundance during 1 week of sow lactation. The fate of PMOs in the 
intestine of piglets after 1-2 days and 1 week of nursing was also investigated. PMOs were 
characterized and quantified using a combination of capillary electrophoresis with 
fluorescence or using mass spectrometry detection and liquid chromatography with mass 
spectrometry detection. 
Materials and methods 
Oligosaccharide standards and capillary electrophoresis analysis kit 
Xylose, glucose, galactose, maltotriose, 3’- and 6’-sialyllactose, 3’- and 6’-sialyl-N-
acetyllactosamine and lacto-N- fucopentaose-V were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). Lacto-N-tetraose, 3’-, 4’- and 6’- galactosyllactose were bought 
from Carbosynth (Compton, UK). Lactose-N-neotetraose, 3’-fucosyllactose, lacto-N-
neohexaose, lacto-N-hexaose, lacto-N-fucopentaose-I,-II and- III, lacto-N-
difucosylhexaose, lacto-N-fucohexaose-III and sialyllacto-N-tetraose-a,-b and -c were 
purchased from Dextra Laboratories (Reading, UK). Labeling of oligosaccharides was 
performed using the Carbohydrate Labeling & Analysis Kit (Beckman Coulter, Fullerton, 
CA, USA). All other chemicals were of analytical grade. Millipore water (Millipore, 
Darmstadt, Germany) was referred to in the text as water. 
Colostrums and fecal samples  
Eight milk samples from Dutch-Landrace sows were collected within 0.5-2 days and at 1 
week postpartum, and frozen (-20oC) until use. Milk samples collected within 0.5-2 days 
postpartum are referred to as colostrum, while milk samples collected at 1 week postpartum 
are referred to as mature milk. Two colostrum samples were donated by Animal Nutrition 
(ANU) group (Wageningen University, Wageningen, The Netherlands), while six samples, 
of which 4 colostrum and 2 mature milk samples, matching the corresponding colostrum 
samples, were donated by proefaccommodatie de Tolakker (Utrecht University, Utrecht, 
The Netherlands). Individual fecal samples were collected from three piglets, 1-2 days and 
1 week old (proefaccommodatie de Tolakker), and stored at -80 oC until use. 
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Extraction, purification and fractionation of PMOs 
Milk samples 
In order to obtain a representative sample containing PMOs, colostrum samples (5ml) were 
pooled and the carbohydrates were extracted as reported previously.1 After carbohydrate 
extraction, solutions were freeze-dried. Two methods were used in order to remove lactose 
from the extracted carbohydrates: size exclusion chromatography (SEC) for qualitative 
analysis and solid phase extraction (SPE) for quantitative analysis.  
SEC was used to obtain pools of PMOs with different degrees of polymerization (DP). In 
total, extracted carbohydrates (200 mg) were fractionated on three Superdex 30 Hiload 
26/600 preparative grade columns (GE Healthcare, Pittsburgh, PA, USA) connected in 
series, using an AKTA Purifier (GE Healthcare) as previously reported.1 In total, 4 SEC 
pools were obtained: SEC pools 1 and 2 contained mainly acidic PMOs, while SEC pools 3 
and 4 contained mainly neutral PMOs. After freeze drying, the resulting pools were re- 
solubilized in 1 mL of water, and the solutions were used for PMO characterization. Part of 
the SEC pools was recombined, in order to have a representative PMOs mixture with 
reduced lactose content (lactose-free PMOs). Another part of SEC pools, as well as lactose-
free PMOs were labeled with APTS and subsequently analyzed by CE-LIF and CE-MSn. A 
third part of each SEC pool and lactose-free PMOs, was analyzed using HILIC-MSn 
without prior labeling. Oligosaccharide standards and a human milk oligosaccharide 
mixture as characterized in a previous study, were used as reference for the characterization 
of PMOs.18  
For quantitative analysis, SPE was used. The carbohydrates extracted from individual 
colostrum and mature milk samples (1mL of 1 mg/mL solution) were loaded onto an 
activated graphitized carbon cartridge (150 mg bed weight, 4 mL tube size; Grace, 
Deerfield, IL, USA). Activation of the SPE cartridges, lactose removal and 
oligosaccharides elution was performed as reported previously.1 The fractions obtained 
containing PMOs were dried overnight under a stream of nitrogen and afterwards 
solubilized in 0.5 mL of water. 
Fecal samples 
Fecal samples (±100 mg) were defrosted and the slurries were diluted in water (2 mL). The 
suspensions were rotated head over tail overnight (4oC) and afterwards they were 
centrifuged (15 min, 15000g, 4oC). The supernatants were collected and filtered through a 
0,22 μm cellulose acetate membrane (GE Healthcare). Fecal enzyme inactivation was 
performed by boiling the solutions (5 min at 100oC), and samples were purified using SPE 
as reported elsewhere.18 The fractions obtained from fecal samples were dried overnight 
under a stream of nitrogen and afterwards solubilized in 0.5 mL of water. 
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Capillary electrophoresis with laser induced fluorescent detection (CE-LIF)  
The PMOs obtained, either after SEC or SPE, were labeled with 9-aminopyrene-1,4,6-
trisulfonate (APTS) and analyzed by CE-LIF as reported elsewhere.19 CE-LIF peaks were 
integrated manually using Chromeleon software 6.8 (Dionex, Sunnyvale, CA, USA). 
APTS-labeled PMOs were quantified using xylose as internal standard. A linear correlation 
between CE-LIF peak areas and oligosaccharide molar concentrations has been 
demonstrated previously.1, 19 After manual peak integration, the peak areas were converted 
into the corresponding PMO concentrations (g/L). 
Capillary electrophoresis with mass spectrometer detection (CE-MSn)  
APTS-labeled SEC PMO pools were analyzed by CE on a PA 800 plus system (Beckman 
Coulter) coupled to an ion-trap mass spectrometer (LTQ Velos Pro ion trap MS, Thermo 
Scientific, Waltham, MA, USA). The CE-MSn analysis was performed as previously 
reported.19  
Hydrophilic interaction liquid chromatography with mass spectrometry detection 
(HILIC-MSn) 
In order to analyze PMOs present in minor abundances in the milk samples, non-labeled 
SEC PMO pools were analyzed by HILIC-MSn as previously described, with some 
modification.1 The mobile phases used were: A = water + 1% (v/v) acetonitrile (ACN), B = 
ACN, and C = 200 mM ammonium formate buffer (pH 4.5). A flow rate of 300 µL/min 
was used. Mobile phases were eluted according to the following profile: 0-1 min isocratic 
85% B; 1-31 min from 85-60% B; 31-35 min from 60-40% B; 35-36 min isocratic 40% B; 
36-36.1 min from 40-85% B; 36.1-45 min isocratic 85% B. The mobile phase C was kept 
constant at 5% during the entire gradient. The auto-sampler and column oven were kept at 
15 and 35°C, respectively. Mass-spectrometric data settings were: ion transfer tube 
temperature of 350˚C and 3.5 kV source voltage, capillary temperature of 350˚C and source 
heater temperature of 225 °C. MS data in negative ion mode were collected over a m/z 
range of 300-2000. The mass spectrometer was tuned using maltotriose (0.3 mg/mL) in 
70:30 (v/v) ACN/water containing 5% (v/v) 200 mM ammonium formate buffer (pH 4.5). 
Results and Discussion 
Characterization of porcine milk oligosaccharides 
In order to elucidate the structure of porcine milk oligosaccharides (PMOs), colostrum 
samples from different sows were collected and pooled. As shown elsewhere, fractionation 
by size exclusion chromatography of mammalian milk oligosaccharides (MMOs) facilitates 
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their characterization by increasing signal to noise ratio during the analysis.1, 7, 16 For most 
of the PMOs, full structural characterization was possible by comparing elution times of 
PMOs with those of available standards using CE-LIF and HILIC-MSn, and by comparing 
mass spectrometric fragmentation data in HILIC-MSn with those described elsewhere.1 All 
PMOs found are listed in Table 1, where the novel PMO structures are highlighted in bold. 
In total, 35 PMOs were annotated of which 19 were neutral, 15 were sialylated and 1 was 
phosphorylated. Comparing the outcomes of this study with previous literature on porcine 
milk,7, 16 13 of the 35 PMOs were novel: neutral HexNAc-Hex, 4'-galactosyllactose, 
putative GalNAc(3)Gal(4)Glc, lacto-N-fucopentaose-II, lact-N-tetraose, 
galactose linked to lacto-N-neohexaose, lacto-N-hexaose and difucosyl-lacto-N-hexaose, 
and acidic Neu5Ac(2-6)GlcNAc1-3)Gal1-4)Glc, sialyllacto-N-tetraose-a and -b, 
NeuAc2-Hex3 and sialyllacto-N-fucopentaose-II. For 3 PMOs (numbers 7, 12 and 31, Table 
1) only partial characterization was possible. PMO number 7 is a trisaccharide, as 
concluded from mass spectrometry. Comparing this finding with literature reporting on 
trisaccharides in cow, goat, sheep and horse milk,7 the trisaccharide in porcine milk was 
assigned putatively to Gal(1-3)Gal(1-4)Glc. PMO numbers 12 and 31 were assigned 
putatively to novo-lacto-N-pentaose-I (novo-LNP-I) and sialyl-novo-LNP-I as literature on 
domestic animal milks report solely the presence of a neutral pentameric structure: novo-
LNP-I.7, 16, 17 Proportionally, PMOs comprise almost twice as many sialylated structures as 
human milk oligosaccharides (HMOs), 43% and 20%, respectively. In colostrum, sialylated 
PMOs is comparable to those in other MMOs, being 60-90, 57, 51 and 20-52% of all 
MMOs reported for cow, goat, sheep and horse colostrum, respectively.1, 7 The opposite 
trend is noticed for fucosylated structures, which covered 24% of all PMO structures and 
about 70% of HMOs.20 Fucosylated PMOs are numbers 2, 3, 8, 13, 14, 19, 32 in Table 1.16 
Regarding the number of structures, PMOs showed a higher proportion of fucosylated 
structures when compared with other domestic animal MMOs, being fucosylated for 8, 8, 7 
and 5% for cow, sheep, goat and horse colostrum, respectively.7 19 of the 35 PMOs showed 
structural overlap with structures present in human milk, as indicated in Table 1. Eight 
PMOs carried the so-called bifidogenic factor (Gal(1-3)GlcNAc) and, therefore, were 
considered potential prebiotic (PMOs numbers 10, 13, 14, 16, 19, 27, 28, 32 in Table 1).20 
An overview of PMO characteristics is presented in Table 2. One molecule of lactose 
carrying a phosphorylated group was observed (PMO number 35 in Table 1). This 
phosphorylated oligosaccharide has been reported to be present in ovine, caprine and 
equine milk, representing only 1-2 % of the total milk oligosaccharides structures.7, 17, 21 
This is the first time that it has been identified in porcine milk.7, 16, 17  
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Table 1. Overview of porcine milk oligosaccharides found in this study. 
 
Ref = reference. HMOs = human milk oligosaccharides. * = PMOs isomer not further specified; 
structure names in Italic = putative isomeric PMO structure. Structures in bold: PMOs novel for the 
porcine milk literature.7, 16 
 
Milk oligosaccharides in porcine milk  
No. proposed structure 
molecular 
weight 
Ref. 
PMOs 
Ref. 
HMOs 
  neutral 
   
1 HexNAc-Hex 383 
  
2 2'-FL 488 7 20 
3 3'-FL 488 7 20 
4 3'-GL 504 7, 16 20 
5 4'-GL 504 16 20 
6 6'-GL 504 7 20 
7 Gal(1-3)Gal(1-4)Glc 504 7  
8 3'-FLN 529 7  
9 GalNAc(1-3)Gal(1-4)Glc 545   
10 LNT 707  20, 22 
11 LNnT 707 7, 16 20, 22 
12 Novo-LNP-I 869 7, 16  
13 LNFP- II 852  20, 22 
14 LNFP- III/V 852 7 20, 22 
15 Gal-LNnH 1234   
16 LNH 1072  20, 22 
17 LNnH 1072 7, 16 20 
18 
Gal(α1-3)+Gal(β1-4)GlcNAc(β1-6)[Gal(β1-
3)]Gal(β1-4)Glc 
1031 7  
19 LNDFH 1364  20 
     
  sialylated 
 
  
20 3'-SL 633 7, 16 20 
21 6'-SL 633 7, 16 20 
22 3'-SLN 674 7, 16  
23 6'-SLN 674 7, 16  
24 Neu5Ac(α2-3)Gal(β1-3)Gal(β1-4)Glc  795 7  
25 Neu5Ac(2-6)GlcNAc(1-6)Gal(1-4)Glc 836 7  
26 Neu5Ac(2-6)GlcNAc(1-3)Gal(1-4)Glc 836   
27 LSTa 998  20 
28 LSTb 998  20 
29 LSTc 998 16 20 
30 Neu5Ac-Neu5Ac-Hex-Hex-Hex 1086   
31 S-novo-LNP-I 1160 7, 16  
32 S-LNFP-II 1307   
33 S-LNH* 1363 7, 16 20 
34 FS-LNH* 1509 16 20 
     
  phosphorylated 
   
35 P+lactose 421 
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Table 2. Overview of characteristics of porcine milk oligosaccharides. 
 
HMOs = human milk oligosaccharides; percentages refer to total number of structures identified. 
PMO pattern for different porcine colostrum samples 
The CE-LIF has been recognized as a suitable method for oligosaccharide quantification 
due to its good peak resolution and separation. Therefore, CE-LIF was chosen for 
quantification of PMOs in porcine colostrum samples.19 In the CE-LIF profile, 17 peaks 
were annotated (Figure 1) using migration times of available oligosaccharides standards, of 
characterized PMO-SEC pools (current study) and of previously characterized HMOs.22 In 
addition, CE-MSn data were compared with those of HMOs reported previously.1, 18 The 
most abundant neutral PMO present was the putative Gal(1-3)Gal(1-4)Glc. The 1-3 
linkage has been reported to be present between galactose moieties in oligosaccharides 
from caprine colostrum as well.23 The most abundant acidic PMO was 3’-sialyllactose (3’-
SL), similarly as in horse and cow colostrum.1, 21, 24 Three main PMO peaks, migrating at 
4.76, 5.59 and 5.76 min (Figure 1), could not be characterized. From their migration times 
it can be hypothesized that they are a dimer and two tetramers as present in equine and 
human milk, respectively.1, 25 Using the same annotation as in Figure 1, peaks were 
identified in Figure 2 for all porcine colostrum and mature milk samples. The main PMOs 
present in the CE-LIF profiles were selected for quantitative analysis. The characterized 
PMOs and their corresponding concentrations in the samples are listed in Table 3. 
Comparison of the CE profiles reveals that 9 of the 11 PMOs quantified were present in all 
milk samples, although they highly varied in concentration among the samples. Lacto-N-
neohexaose (LNnH) and sialyllacto-N-hexaose (S-LNH, isomer not further specified) were 
absent in some of the colostrum samples (1M, 4M and 6M) and in mature milk samples 
(1M# and 3 M#). Among the colostrum samples, the total PMO concentrations ranged from 
7.38 to 29.35 g/L. The corresponding values for HMOs, EMOs and bovine milk 
oligosaccharides (BMOs) present in the corresponding colostrums are about 24, 2.8 and 1 
g/L, respectively. Hence, it can be noticed that in this respect porcine colostrum resembles 
human colostrum the most.1, 26 Acidic PMOs represented the most abundant structures, 
No. s tructures  identi fied 35
No. new structures  identi fied 13
neutra l  s tructures 54%
sia lylated s tructures 43%
fucosylated s tructures 23%
phosphorylated s tructure 3%
structura l  overlap with HMOs 54%
Pig mi lk ol igosaccharides
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accounting for 77% of the total amount of PMOs quantified. This finding correspond with 
previous data, in which 82% peak abundance was reported for acidic PMOs.16 
 
Figure 1. CE-LIF electropherogram of PMOs in porcine colostrum (3M). * = PMOs isomer not 
further specified, structures in Italic = putative isomeric PMOs structure. Structures in bold: PMOs 
novel for the porcine milk literature.7, 16, 17. L= lactose, 3'-, 4'-, 6'-GL=3'-, 4'- ,6'-Galactosyllactose, 
3’-FL = 3’-fucosyllactose, LN(n)T = lacto-N-(neo)tetraose, LNFP-II, III, V = lacto-N-fucopentaose-
II, III, V, LSTa, b, c = sialyl-lacto-N-tetraose-a, -b, -c, LNDFH = lacto-N-difucohexaose, S-LNH = 
sialyllacto-N-hexaose, LN(n)H = lacto-N-(neo)hexaose, Gal-LNnH= galactose-sialyllacto-N-
neohexaose.  
The relative high contribution of acidic structures in colostrum has been also shown for 
BMOs, for which the abundance of acidic and neutral structures is 70-91 and 9-30%, 
respectively.7, 27 In all porcine colostrum samples, the most abundant PMOs was the acidic 
3’-SL, with a concentration ranging from 5.03 to 20.98 g/L, representing 68-71% of the 
quantified PMOs. 3’-SL is also the most abundant oligosaccharide in cow colostrum (about 
49% of the total colostral BMOs), while it is a minor component in human colostrum.7, 15, 25  
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Figure 2. CE electropherograms of PMOs from six porcine milk samples. 1-6 M= porcine colostrum, 
1 and 3 M# = porcine mature milks. * = PMOs isomer not further specified, structures in Italic = 
putative isomeric PMOs structure. Structures in bold: PMOs novel for the porcine milk literature.7, 16, 
17. L= lactose, 3'-, 4'-, 6'-GL=3'-, 4'- ,6'-galactosyllactose, 3’-FL = 3’-fucosyllactose, LN(n)T = 
lacto-N-(neo)tetraose, LNFP-II, III, V = lacto-N-fucopentaose-II, III, V, LSTa, b, c = sialyl-lacto-N-
tetraose-a, -b, -c, LNDFH = lacto-N-difucohexaose, S-LNH = sialyllacto-N-hexaose, LN(n)H = lacto-
N-(neo)hexaose, Gal-LNnH = galactose-sialyllacto-N-neohexaose. 
Variation of PMOs during lactation 
Having two porcine mature milks available matching the corresponding colostrum samples, 
a first inventory comparing PMO composition of colostrum and mature milk was conducted 
(1M-1M# and 3 M-3M#, for colostrum and mature milk, respectively, Table 3). Overall, the 
PMO concentrations decreased from 11.86-12.19 g/L in the porcine colostrum to 6.82-6.98 
g/L in the mature milk samples (Table 3). This reduction corresponds with data for BMOs 
and HMOs reporting a decrease of about 56% of milk oligosaccharides within the initial 14 
days of lactation.17, 26 In those studies no information on the decrease of individual 
oligosaccharides was reported.15, 28  
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Table 3. Presence and concentration (g/L) of PMOs in colostrum and mature milk (#) of six sows. 
 
* = PMOs isomer not further specified, structure names in Italic = putative isomeric PMO structure. 
Structures in bold: PMOs novel for the porcine milk literature.7, 16, 17 ; − = not present. 
In the current study, levels of individual PMOs highly varied depending on the milk 
analyzed. Nevertheless, abundance of some PMOs showed comparable trend in 
concentration from colostrum to mature milk samples: putative (1-3)Gal(1-4)Glc, 3'-SL 
and S-LNH (isomer not further specified) decreased in concentration, while 3'-GL, LNnT 
and SLTa increased in concentration. Overall, in porcine milk, proportion of sialylated 
PMOs decreased from 77% to 49% of the total PMOs, for colostrum and mature milk 
samples, respectively, being in accordance with previous literature.16 For sialylated BMOs 
also a decrease of about 30% has been observed.15, 29 The proportion of neutral PMOs 
increased from 23% to 58% of the total PMOs, for colostrum and mature milk samples, 
respectively. Neutral BMOs have been shown to increase about 40% in concentration 
during the first 6 days postpartum.15  
Fermentation of PMOs 
In order to investigate PMO fermentation, fecal samples from piglets were collected after 1-
2 days and after 1 week of nursing. Oligosaccharides present in fecal samples were 
analyzed by CE-LIF and HILIC-MSn and their levels were correlated with those of the 
corresponding milk samples. In Figure 3, CE profiles of PMOs from fecal samples of three 
piglets per sow (f-1a-c, f-6a-c) fed for 1 day on the corresponding porcine colostrum (1M and 
6M) are shown. CE profiles of oligosaccharides of fecal samples showed only five intact 
PMOs: 3’-SL, LSTa LNT, LNnT and LNFP-II, with quite some individual variation in 
 1 
PMOs concentration in colostrum and mature milk 
  
               
  1M 
 
1M# 
 
2M 
 
3M 
 
3M# 
 
4M 
 
5M 
 
6M 
  
               
Neutral 
               
6'-GL 1.09 
 
0.94 
 
0.97 
 
0.64 
 
1.23 
 
0.73 
 
0.83 
 
0.69 
3'-GL 0.69 
 
1.20 
 
1.68 
 
0.19 
 
1.42 
 
0.34 
 
0.59 
 
1.98 
Gal(1-3)Gal(1-4)Glc 1.04 
 
0.47 
 
3.61 
 
0.73 
 
0.57 
 
0.07 
 
1.11 
 
0.23 
LNnT 0.13 
 
0.22 
 
0.34 
 
0.07 
 
0.31 
 
0.15 
 
0.21 
 
0.09 
LNT 0.06 
 
0.07 
 
0.14 
 
0.07 
 
0.03 
 
0.07 
 
0.08 
 
0.05 
LNnH ― 
 
― 
 
0.28 
 
0.30 
 
― 
 
― 
 
0.43 
 
0.10 
GAL-LNnH 0.45 
 
0.72 
 
0.54 
 
0.19 
 
0.79 
 
0.84 
 
0.50 
 
0.67 
  
               
Acidic 
               
3'-SL 7.60 
 
3.05 
 
20.98 
 
9.48 
 
1.86 
 
5.03 
 
17.93 
 
10.67 
Neu5Ac(2-6)GlcNAc(1-
6)Gal(1-4)Glc 
0.59 
 
0.10 
 
0.24 
 
0.13 
 
0.48 
 
0.02 
 
1.05 
 
0.29 
SLTa 0.08 
 
0.20 
 
0.25 
 
0.10 
 
0.12 
 
0.12 
 
0.16 
 
0.10 
S-LNH* 0.13 
 
― 
 
0.32 
 
0.29 
 
― 
 
― 
 
0.40 
 
― 
  
               
Total PMOs 11.86 
 
6.98 
 
29.35 
 
12.19 
 
6.82 
 
7.38 
 
23.28 
 
14.87 
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content. Next to the identified PMOs, several oligosaccharides with DP3 and DP4, as 
suggested from their CE peak migration times (min 5-6, Figure 3), were observed.  
  
Figure 3. CE electropherograms of fecal PMOs (f-1a-c, and f-6a-c) from 3 piglets fed 1 day on 
corresponding porcine colostrum (1M, and 6M). Structures in bold: oligosaccharides novel for the 
porcine milk literature.7, 16, 17 3’-SL = 3’-sialyllactose, LN(n)T = lacto-N-(neo)tetraose, LSTa, = 
sialyl-lacto-N-tetraose-a, LNFP-II = lacto-N-fucopentaose -II. 
Using mass spectrometry, however, no specific structures could be assigned to these 
oligosaccharides. Since piglets were exclusively fed on colostrum, it can be hypothesized 
that the unidentified oligosaccharides were fermentation products derived from PMOs. 
Already at the first day of life, piglet feces lack intact PMOs, indicating quite some 
intestinal fermentation. Differently, infant feces have been described to present intact 
dietary HMOs, even after 2 months of life.22 As reported previously, already within 12 h 
after piglet birth, bacteria colonize the colon of piglets (109 -1010 bacteria/g colonic 
content) and within 2 days piglet microbiota could already be established.30, 31 A 
decrease of about 41% in CE-LIF peak area was found for oligosaccharides present in feces 
of 1 week old piglets (data not shown) compared with 1 day old piglets. By HILIC-MSn, 
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only one other dimer with a Hex-NAcHex structure, in addition to 3’-SL, was recognized 
(data not shown) in fecal samples from 1 week old piglets. 
In conclusion, 35 PMOs were recognized in porcine colostrum, of which 13 structures were 
found for the first time.7, 16, 17 Eleven major PMOs were quantified individually showing 
high inter-individual PMO variation, both regarding their presence and abundance in 
porcine milk samples. An overall decrease in abundance of about 43% was found among 
the major PMOs during the first week of lactation, confirming the trend already found for 
cow milk.15 However, while the concentration of acidic PMOs decreased, that of neutral 
PMOs increased. Already during the first days of life, fecal samples of piglets contain only 
few intact PMOs, which are not present anymore in fecal samples of 1 week old piglets. 
Fecal oligosaccharides different from PMOs were recognized, indicating PMO 
intestinal fermentation products. 
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Chapter 4 
Oligosaccharides in urine, blood and feces of 
piglets fed on milk replacer containing 
galacto-oligosaccharides 
 
 
 
Abstract 
Human milk oligosaccharides (HMOs) are absorbed into the blood (about 1% of the HMOs 
intake) and subsequently excreted in urine, where they may protect the infant from 
pathogen infection. As dietary galacto-oligosaccharides have partially structural similarities 
with HMOs, this study investigated the presence of galacto-oligosaccharides (GOS) and 
oligosaccharides originating from milk replacer in blood serum, urine, cecal and fecal 
samples of piglets, as model for infants. Using liquid chromatography mass spectrometry, 
and capillary electrophoresis with fluorescence detection, oligosaccharides originating from 
piglet diet including 3’-sialyllactose and specific GOS ranging from degree of 
polymerization 3 to 6 were detected in blood serum and in urine of piglets. In blood serum, 
GOS levels ranged from 16-
urine, approximately 0.85 g of GOS/g of creatinine was found. Cecum digesta and feces 
contained low amounts of oligosaccharides, suggesting an extensive GOS intestinal 
fermentation in piglets. 
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Introduction 
Human milk oligosaccharides (HMOs) are the third most abundant component in milk, 
after lactose and lipids.1 About 200 different HMOs have been annotated, of which around 
100 oligosaccharide structures have been elucidated.1, 2 After oral ingestion of human milk, 
about 1% of HMOs, both neutral and acidic, are reported to be absorbed in the small 
intestine of the infant, thereafter entering the blood circulation. So far, about 15 HMOs, 
including lacto-N-tetraose, lacto-difucosyl-pentaose, 3’-, and 6’-sialyllactose, and 3’-, and 
6’-sialyl-N-acetyllactosamine were observed in blood of infants.3 Literature suggest a 
protective function of HMOs in the blood circulation by influencing leucocyte adhesion to 
endothelial cells and platelets-neutrophils interaction.4-6 When systemic HMOs are cleared, 
they are excreted into the urinary system, thus being detectable in urine.5-8 Next to lactose, 
13 HMOs, both neutral and acidic, have been found in urine of infants.6 One of the 
proposed functions of HMOs is an in-situ protection against urinary tract infections in the 
infant, by blocking the adhesion of pathogens to the epithelial cell wall.4, 5 Around 99% of 
the HMOs reach the colon of infants, where they can be fermented by the colonic 
microbiota.9, 10 In the intestine, HMOs can exert prebiotic, immuno-modulatory and anti-
infective functions.11 To date, HMOs are not produced in the food-grade volumes required 
for infant nutrition. Therefore, other dietary ingredients that promote health and wellbeing, 
and reduce the risk of diseases are of broad public interest.12 Non-digestible 
oligosaccharides, such as galacto-oligosaccharides (GOS), belong to these health promoting 
ingredients. Multiple preclinical studies have shown that GOS is a prebiotic fiber that 
selectively stimulates the growth of beneficial gut bacteria.13-18 Different studies have 
shown that daily ingestion of GOS increases beneficial bacteria, such as bifidobacteria, in 
the colon of adults and infants.13, 16, 19 It is hypothesized that GOS lowers the 
gastrointestinal pH and reduces the survival of pathogens.13, 20-22 Moreover, GOS 
fermentation by intestinal microbiota leads to the production of short chain fatty acids, 
including butyrate.17 Butyrate is known for decreasing inflammation, carcinogenesis and 
oxidative stress in the intestine.23, 24 GOS are also acting as soluble ligands for pathogens, 
inhibiting for example the binding of Escherichia coli and Salmonella typhimurium to the 
intestinal mucosa layer.25 In addition, GOS are associated with a lower risk of infections 
and diarrhea due to direct effects on the intestinal immune system.17 Moreover, the 
microbiota of infants fed on formula enriched with GOS or galacto-/fructo-oligosaccharides 
(FOS) resembled more the microbiota of infants breast-fed, than microbiota of infants fed 
on GOS/FOS-free formula.26 The observed GOS health-promoting effects are dose 
dependent, and are a result of their structural characteristics, which have similarities with 
those of HMOs.1, 27, 28 GOS are industrially produced from lactose by β-galactosidase 
enzyme of microbial or fungal origin.12 The composition of GOS mixtures varies depending 
on the enzyme source and the conditions used during the production process, such as 
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temperature, pH and substrate concentration.13 GOS mixtures consist of galactose 
oligomers with a terminal glucose, varying in degree of polymerization (DP) and type of 
glycosidic linkage(s).13 The DP ranges mostly between 2 to 8.21 The complex mixture that 
is produced, predominantly consists of structures with a reducing end, but also in minor 
amounts (7% of GOS-DP2) with a non-reducing end.13, 17 Although beneficial health 
effects of GOS have been shown, GOS in vivo fate is not completely known.17, 25 In the 
current study, a pig model was used to investigate absorption, excretion, and fermentation 
of orally ingested GOS making use of biological sample being available from a piglet study 
addressing health benefits of GOS during a 26 days feeding trial.29 
Materials and methods 
Materials  
Monosaccharides and oligosaccharides used as standards were: D-(+)-xylose, D-(+)-
glucose, D-(+)-galactose (Sigma-Aldrich, St. Louis, MO, USA), 3’-, and 6’-sialyllactose 
(Dextra Laboratories, Reading, U.K.), (1-4)-β-D-galactobiose (Megazyme, Bray, Ireland), 
D-(+)-lactose, D-(+)-maltose (Merck, Darmstadt, Germany) and maltodextrine (dextrose 
equivalent 20) (AVEBE, Veendam, The Netherlands). Vivinal® GOS syrup (DM 75%) 
was provided by FrieslandCampina DOMO (Borculo, The Netherlands). Specification by 
the supplier were: dry matter content of 75%, of which 59% galacto-oligosaccharides, 21 % 
lactose, 19% glucose and 1% (w/w) galactose. Fractions of Vivinal GOS (Degree of 
polymerization from 1 to 6) were obtained after size exclusion chromatography (SEC) as 
described elsewhere.30 Sodium cyanoborohydride, trifluoracetic acid (TFA) and 
ammoniumhydroxide were purchased from Sigma (Sigma-Aldrich). UHPLC-grade water 
and UHPLC-grade acetonitrile (ACN) were purchased from Biosolve BV (Valkenswaard, 
The Netherlands). Millipore water was obtained from an Elix Integral water purification 
system (Millipore, Darmstadt, Germany) and it is referred in the text to as ‘water’. 
Experimental animal model and diets used 
The piglet was used as a model to study the effects of GOS on the intestinal functions as 
described in detail elsewhere.29 In short, 40 Landrace × Yorkshire piglets, separated from 
the mother sows 36-48 h postpartum, were selected for this study. The short pre-weaning 
period allowed the intake of colostrum and consequent protection by maternal antibodies. 
After being separated from the sow, the piglets were housed under conventional conditions 
at the animal housing facility of Utrecht University (Department of Farm Animal Health), 
allocated ad random to two experimental groups receiving either the piglet milk replacer 
(control diet) alone or supplemented with GOS. The commercial piglet milk replacer 
(Milkiwean Babymilk Yoghurt, Nutreco, Amersfoort, The Netherlands) contained 965 g/kg 
dry matter, 200 g/kg crude protein, 200 g/kg fat, 0.10 g/kg crude fiber, 3.50 g/kg calcium 
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and 4.80 g/kg phosphorus. Part of the piglet milk replacer was supplemented for the 
experimental group with 0.8% GOS (Vivinal® GOS syrup, FrieslandCampina Domo). 
From each group (control- and GOS-fed piglets) one subgroup of 10 animals was sacrificed 
3 days after the start of the experiment (age of approximately 4-5 days and 3 days on the 
diet), whereas the other two subgroups (control- and GOS-fed piglets) of 10 animals were 
sacrificed 26 days after the start of the experiment (age of approximately 27-28 days and 26 
days on the diet). All in vivo experimental protocols were approved by the Ethics 
Committee for Animal Experiments (Reference number: DEC 2011.III.11.117) and were 
performed in compliance with governmental and international guidelines on animal 
experimentation. 
Collection of fecal, blood, digesta and urine samples 
Piglets, at days 3 and 26 of the experimental feeding period, were sacrificed within 2 h after 
the last feeding. Fecal samples per piglet were collected and directly stored at -80 °C. The 
gastrointestinal tract was removed and the digesta from the cecum were collected and 
stored at -80 °C. Blood from the external jugular vein and urine from the bladder were 
collected and stored at -20 °C.  
Prior to the analysis of GOS in serum samples, extraction and analytical methods, already 
established for milk and food liquid matrixes, were tested on serum samples from 2 pigs 
(Faculty of Veterinary Science, Utrecht University) not belonging to the feeding trial. The 2 
pigs were fed on a diet different from Milkiwean Babymilk with no GOS supplementation. 
A part of the 2 serum samples was spiked with Vivinal GOS (0.08% w/v) and after 
purification and carbohydrate extraction, they were compared with the original serum 
samples. 
Oligosaccharide extraction and purification  
Extraction 
Three randomly chosen serum (500 L) and urine samples (200 L) and Vivinal GOS 
solution (200 L, 1mg/mL) were centrifuged (20000g, 5 min., 20 oC) and the supernatants 
were analyzed. Oligosaccharide extraction from feces and cecal digesta was performed as 
described elsewhere, with minor modifications.31 Briefly, watery slurries of cecal digesta 
and fecal samples (50 mg/mL) were kept overnight at 4 °C under head over tail rotation, in 
order to optimize the carbohydrate extraction. Next, the samples were placed into 
centrifugal filter unit (0.22 µm PVDF, Merck Millipore) and centrifuged (20000g, 15 min, 
4 °C). The filtrate was heated (5 min, 100°C) and used as sample. The filtrates (digesta and 
fecal samples) and the supernatants (serum and urine samples) were diluted in 2 mL water. 
Piglet formula Milkiwean Babymilk Yoghurt (2 mg) was suspended in water (1 mg/mL) 
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and subsequently was centrifuged as described above. This supernatant was used as control 
sample for further analysis. 
Purification 
Monosaccharides and salts present in all samples were removed by Solid Phase Extraction 
(SPE) on non-porous graphitized carbon cartridge (bed weight; 150 mg, tube size; 4 mL; 
Alltech, Deerfield, IL, USA). The cartridges were conditioned with 1.5 mL of 80:20 (v/v) 
acetonitrile (ACN)/ water containing 0.1% (v/v) trifluoroacetic acid (TFA), followed by a 
washing step with 1.5 mL water, as reported elsewhere.32 Samples and GOS solution, 
obtained as described above, were loaded onto the cartridges. Salts and monosaccharides 
were removed by elution with 6 mL of water. Oligosaccharides, including disaccharides, 
were collected after elution with 3 mL of 40:60 (v/v) ACN/ water containing 0.05% (v/v) 
TFA. The eluted oligosaccharide fraction was dried overnight under a stream of nitrogen at 
20 oC and re-solubilized in 500 µL water (Vivinal GOS, milk replacer, urine, feces and 
cecal digesta) or in 200 µL water (serum samples). After SPE, the Vivinal GOS solution, 
presenting a reduced amount of monomers (glucose and galactose), is coded GOS ref and is 
used as a standard for comparative analysis within the current study. 
Analysis of oligosaccharides by Capillary Electrophoresis with Laser Induced 
Fluorescence detection (CE-LIF) 
Fractions of GOS, and oligosaccharides from serum, urine, feces and cecal digesta samples 
of 3 piglets of each experimental group (from 3 and 26 days on control or GOS diet) were 
analyzed. Purified oligosaccharides were labeled as reported elsewhere using a Proteomelab 
Carbohydrate Labeling and Analysis Kit (Beckman Coulter, Fullerton, CA, USA).30 Five 
nanomoles of xylose were added as internal standard to 100 µL of sample. According to 
manufacturer’s instructions, the labeled samples were diluted 40 times prior to CE-LIF 
analysis, and the electropherograms were normalized on the internal standard. Data analysis 
was performed with Chromeleon software 6.8 (Dionex, Sunnyvale, CA, USA). The degree 
of polymerization of individual GOS components was recognized by comparing the 
obtained CE-LIF profiles with known SEC GOS-DP fraction profiles.33  
Analysis of oligosaccharides by Hydrophilic Interaction Liquid Chromatography 
with mass detection (HILIC-MSn) 
The oligosaccharide samples were solubilized 1:1 (v/v) in ACN and analyzed using an 
Accela Ultra High Pressure Liquid Chromatography (UHPLC) system (Thermo Scientific, 
Waltham, MA, USA). Chromatographic separation was performed on an Acquity HILIC 
BEH Amide column (1.7 μm, 2.1 mm × 150 mm) combined with a Van Guard precolumn 
(1.7 μm, 2.1 mm × 5 mm; Waters Corporation, Milford, MA, USA). The flow rate was 300 
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μL/min and the injection volume was 5L. The eluents were: (A) water with 1% (v/v) 
ACN, (B) 100% (v/v) ACN and (C) 200 mM ammonium formate (pH 4.5). Separation was 
achieved under the following condition: 0-31 min, from 10 to 35% (v/v) A; 31-36 min, 
from 35 to 55% (v/v) A; 36-45 min, from 55 to 10% A. Eluent C was kept constant at 5% 
during the separation. Temperatures of the auto-sampler and column oven were set at 20 °C 
and 35 °C, respectively. In-line mass spectrometric analysis was performed using a Velos 
Pro mass spectrometer (Thermo Scientific) coupled to the UHPLC system described above. 
Mass-data were acquired in negative ionization mode over a m/z scan range of 300-2000 
Da. MS2 and MS3 fragmentation were performed on the most abundant ion in the MS and 
MS2 spectrum, respectively. 
Oligosaccharides estimation in blood and urine of piglets 
In order to roughly estimate the oligosaccharides absorption in blood and excretion in urine, 
several parameters were considered. Piglet blood was estimate to be 13% of body weight 
and serum was estimated to be 60% of blood volume.34 After 3 and 26 days GOS-diet, the 
average serum volume was estimated to be 151 and 595 ml, respectively, with a piglet body 
average weight of 1.9 (3 days) and 7.2 kg ( 26 days). Piglets feedings were approximately 
600 ml/piglet/day at the start of the experiment increasing to approximately 1600 
ml/piglet/day during the experimental period. Systemic GOS was expressed as percentage 
of GOS absorbed during the daily mean GOS intake. Urine samples are an easily available 
source for compound estimation in urine, however variation in compound concentration in 
urine is present. Oligosaccharide urinary concentration was adjusted by relating it to the 
creatinine concentration in the same urine sample.35 Creatinine is a metabolic product of 
muscle tissue and is almost constantly excreted in urine. Therefore, the urinary 
oligosaccharide concentration was expressed as grams of GOS/gram of excreted creatinine, 
calculated for each analyzed urinary sample.35 Amount of oligosaccharides in the biological 
samples was determined using CE-LIF. Quantification of APTS-labeled oligosaccharides 
was performed converting the peak areas via amount of nanomoles to amount of 
micrograms.30 The amount (µg) per DP, and per individual compound was calculated 
relative to the total amount (µg) of GOS-DP3-6 present in the samples analyzed.  
Results and Discussions 
Characterization of Vivinal GOS syrup 
Vivinal GOS syrup, used as source of GOS in the experimental feeding trial, was 
characterized prior to piglet samples analysis. GOS ref., GOS-SEC fractions and relevant 
oligosaccharide standards were APTS-labeled and analyzed by CE-LIF. Comparing GOS-
SEC fraction electropherograms with previous literature, GOS peaks were recognized for 
their degree of polymerization (DP) and were numbered (1-29, Figure 1).33 Peak numbers 
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were used in further comparative data analysis in this paper. Peaks 1, 2 and 3 were assigned 
to glucose, galactose and lactose, respectively. GOS-DP3 (peaks 6-12), GOS-DP4 (peaks 
13-22), GOS-DP5 (peaks 23-28) and GOS-DP6 (peak 29) peaks were assigned based on 
previous data.33 The presence of seven GOS-DP3 with a free reducing end is in agreement 
with previous data.13 Quantification of GOS having specific DP was performed on APTS-
labeled Vivinal GOS syrup. The abundances of GOS-DP2-6 were 40, 24, 11, 4, and <1% 
(w/w), respectively, in accordance with literature.13, 33 Hence, it can be concluded that GOS 
were reliably separated and quantified by CE-LIF, allowing further analysis of biological 
samples.  
 
Figure 1. CE–LIF electropherogram of the GOS ref. The detected GOS peaks are numbered from 1-
29, and the internal standard xylose was indicated with a star (*). DP = degree of polymerization. 
Extraction and detection of GOS in serum samples  
Previous studies have indicated that neutral oligosaccharides could be purified by solid 
phase extraction (SPE) when present in liquid food matrices, urine, digesta and feces, 
although to our knowledge it was never investigated for serum samples.32, 33, 36 Therefore, 
extraction and purification of GOS from the serum of 2 piglets not belonging to the piglet 
feeding trial were performed prior to serum samples analysis from the feeding trial. 
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Recovery of GOS was examined by spiking piglet sera with Vivinal GOS (0.08% w/v). As 
shown in Figure 2, the CE-electropherograms of the spiked serum samples and GOS ref. 
were comparable. The total GOS peak area were compared and a recovery of ~97% of 
added GOS to serum samples was achieved. In the non-spiked serum samples, next to 
glucose and galactose, only trace amounts of oligosaccharides (eluting from 5 to 6 min., 
Figure 2) were observed. Consequently, it can be concluded that SPE is a successful 
method to extract and purify GOS from serum samples prior to CE-LIF analysis.  
 
Figure 2. CE-LIF electropherograms of oligosaccharides from piglet serum, from piglet serum spiked 
with 0.08% of GOS, and from GOS 0.08%. The electropherograms were normalized on the internal 
standard xylose (*) and GOS peaks were numbered from 1 to 29 as in Figure 1. DP = degree of 
polymerization. 
GOS and dietary oligosaccharides in the biological samples: 
Detection of oligosaccharides in serum at day 3 by CE-LIF 
In Figure 3, CE-LIF profiles of APTS-labeled oligosaccharides from serum samples of 
piglet fed 3 days on GOS or control diet (S-A1 and S-B1, respectively) are compared with 
those of GOS ref. and milk replacer control. Both in S-A1 and S-B1 sample, peaks 
representing reducing oligosaccharides were observed: in S-A1, besides dimers including 
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lactose, peaks were assigned specifically to GOS structures (numbers 6-29, Figure 3). Peak 
numbers 6-12, 14-21, and 23-29 in Figure 3 were assigned to GOS-DP3, -DP4, and ≥ -DP5, 
respectively. Abundance of the detected GOS will be discussed below.  
 
Figure 3. CE-LIF electropherograms of GOS ref., milk replacer; oligosaccharides present in serum at 
day 3 of GOS diet (S-A1), and control diet (S-B1). DP = degree of polymerization based on GOS. 
The electropherograms were normalized on the internal standard xylose (*); 6-29: peaks 
corresponding to GOS; a-z: peaks as found in S-B1, capital letters represents oligosaccharides 
possibly derived from the milk replacer. 
In addition, dietary acidic oligosaccharide 3’-sialyllactose (3’-SL) present in the milk 
replacer was recognized in serum samples of piglets fed on control and on GOS diet (peak-
a, Figure 3). 3’-SL, reported to be one of the most abundant oligosaccharides in cow’s milk 
(95 mg/L), represented approximately 0.8 and 1.3 % of the total oligosaccharides, 
excluding lactose, present in serum samples of piglets fed 3 days on GOS or control diet, 
respectively.12 None of the oligosaccharide peaks assigned to GOS were present in the 
serum samples of piglet fed on control diet (S-B1). Surprisingly, S-B1 showed the presence 
of additional 25 reducing oligosaccharides (peaks named b-z, Figure 3). Most of them were 
present in very low abundance, although peak-t was present in high abundance. Comparing 
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migration times, it was hypothesized that, beside 3’-SL, 11 of the 25 peaks were 
specifically originating from the milk replacer (capital letters in Figure 3). Peak-7 in S-A1, 
being present in a comparable relative amount to peak as observed in the GOS ref., was 
assigned to a GOS structure. However, peak-7 was overlapping with the un-resolved peak-h 
present in low abundance in serum S-B1of the control group. To the best of our knowledge, 
this is the first time that GOS and oligosaccharides present in a piglet milk replacer are 
detected in piglet blood samples. Systemic presence of HMOs and neutral oligosaccharides 
from cow milk after ingestion of infant formula have been described previously.3 In this 
study, oligosaccharides added to the piglet formula were found to be absorbed and excreted, 
comparable to HMOs in infants.  
Detection of oligosaccharide in serum at day 3 by HILIC-MSn 
Since this is the first time that GOS have been detected in serum samples, HILIC-MSn was 
used to confirm these results. In Figure 4, profiles of oligosaccharides in serum of piglets 
fed 3 days on GOS or control diet (S-A1 and-B1, respectively), GOS ref. and milk replacer 
control are shown. Based on profile comparison, especially GOS DP3 and DP4 were 
present in serum of GOS-fed piglets (S-A1). Due to their extremely low abundance, GOS-
DP5 present in the serum samples could not be assigned to specific oligosaccharides. In 
serum sample profiles, peaks representing oligosaccharides eluting around 30 minutes were 
also detected. Nevertheless, their masses did not correspond to oligosaccharides with DP6 
or 7, as expected from their elution times. From MS2 fragmentation analysis, they were 
suggested to present 2 neutral hexose trimers and one unsaturated hexose monomer. In 
Figure 5, an example of mass analysis of oligosaccharides observed in serum samples of 
piglets fed 3 days on GOS or control diet (S-A1 and B1, respectively), the GOS ref. and 
milk replacer control are shown. MS2 fragmentation patterns and structural composition of 
the trimers named A, B, C and D are also presented and fragments were annotated as 
suggested elsewhere.37 All the hexose trimers, having formate adduct, presented a mass-
over-charge (m/z) of 549. The chromatograms of serum of piglets fed on GOS diet (S-A1) 
showed a specific peak overlap with GOS ref. peaks (15-22 min.). On the contrary, in the 
profile of serum from piglets fed on control diet (S-B1), only one trimer was observed (19 
min.). The highest peak for each sample was compared for its fragmentation pattern. The 
highest intensity peaks C (S-A1) and D (GOS ref.) were attributed to fragment with m/z 
425 referring to intra-ring hexaose fragmentation. Fragments with a m/z 161, and 179, 
representing monomeric units, moreover, showed a comparable relative abundance (ratio 
161:179 m/z of 6.5 and 5.3, respectively). In contrast, highest intensity peaks in A (milk 
replacer) and B (S-B1) were attributed to a m/z 503 referring to trimers deprived of the 
formate adduct. Fragments with m/z 161 and 179 showed a relative ratio of 0.2 and 0.04, 
for peaks A and B respectively, both not comparable with the ratio reported above for peaks 
C and D.  
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Figure 4. Base peak in HILIC-MSn for oligosaccharides as found in GOS ref., in serum at day 3 of 
GOS diet (S-A1) and control diet (S-B1), and in milk replacer. DP = degree of polymerization. 
Subsequent mass analysis of DP4 oligosaccharides proved the GOS contribution to the 
oligosaccharide profile in serum (data not shown) and confirmed that GOS-DP4 was 
present in serum of GOS-fed piglets. HILIC-MSn supported our CE-LIF findings, 
confirming the presence of GOS in serum of piglets fed on GOS diet (S-A1). In the milk 
replacer used in this study, cow’s milk oligosaccharides and neutral hexoses were found. 
Identified cow’s milk oligosaccharides were: 3’- and 6’-sialyllactose, disialyllactose and N-
acetylgalactosaminyllactose.12 After mass analysis, 3’-sialyllactose was observed in serum 
of piglets fed on GOS and control diet, as expected from CE-LIF analysis. In in vivo 
studies, systemic presence of neutral and acidic oligosaccharides from human milk has been 
reported for suckling human neonates.6, 10 Moreover, in vitro studies showed the passage of 
neutral and acidic milk oligosaccharides through intestinal epithelial cells.10, 38 6’-
Sialyllactose, disialyllactose and N-acetylgalactosaminyllactose detected in the milk 
replacer were not found in serum samples. They are reported to be present in low 
abundance in cow’s milk and, therefore, they were probably below the detection limit. 
Another possibility refers to discrimination in oligosaccharide intestinal absorption or in 
early oligosaccharide fermentation in the small intestine, as suggested by investigation on 
the prebiotic fructo-oligosaccharides.12  
40
Time (min)
0 5 15 20 25 30 35
0
100
0
100
0
100
R
el
at
iv
e 
A
b
u
n
d
an
ce
0
100
10
La
ct
o
se
 
DP2 DP3 DP4 DP5 DP6 DP7
Milk replacer
S-B1
S-A1
GOS ref.
4 
CHAPTER 4 
 
68 
 
 
Figure 5. Selected base peak in HILIC-MSn for trimers as found in GOS ref., in serum at day 3 of 
GOS diet (S-A1) and control diet (S-B1), and in milk replacer. Corresponding MS2 fragmentation 
patterns and fragment annotation, as reported by Domon et al, of the trimers named A, B, C, and D; 
m/z 549 precursor ion in HILIC-MSn.37  
Detection of oligosaccharides in the urine at day 3 by CE-LIF and mass analysis  
After confirmation of GOS presence in serum samples, it was investigated whether GOS 
were excreted in the urinary system of the piglets. Similarly to serum, urine samples of 3 
piglets per feeding group were analyzed by CE-LIF. In Figure 6, CE-LIF 
electropherograms of oligosaccharides present in serum and urine from piglets fed 3 days 
on GOS diet (S-A1 and U-A1, respectively) are compared with the GOS and control diet. 
From the CE profiles, besides dimers including lactose and dietary 3’-sialyllactose (peak a, 
Figure 3), GOS structures were found in urine, which were comparable to the GOS 
structures in serum samples. In the CE-LIF urine profile, peaks assigned specifically to 
GOS were annotated with numbers (peaks 6-29, Figure 6). The CE-LIF outcome for GOS-
DP3-4 was confirmed by liquid chromatography mass spectrometry, in which mass 
fragmentation showed GOS origin of oligosaccharides in piglet serum and urine (data not 
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shown). Abundance of the detected GOS structures will be discussed in the next paragraph. 
To our knowledge, excretion of GOS structures in urine of GOS-fed animals has not been 
shown before. Nevertheless, the presence of dietary HMOs and prebiotic fructo-
oligosaccharides was described for urine of infants and adults, respectively.7, 8, 39, 40 
Concerning HMOs, both neutral (fucosyllactose, lacto-N-tetraose, lacto-N-fucopentaose 
and lacto-difucosylpentaose) and acidic (3’, and 6’-SL, 3’-, and 6’-sialyl-N-
acetyllactosamine) dietary HMOs were found in urine samples of infants, indicating HMOs 
systemic absorption.3, 6  
Figure 6. CE-LIF electropherograms of GOS ref, milk replacer, oligosaccharides from serum and 
urine at day 3 of GOS diet (S-A1 and U-A1, respectively) and urine at day 3 of control diet (U-B1). 
DP1-5 = degree of polymerization based on GOS. The electropherograms were normalized on the 
internal standard xylose (*); 6-29: peaks corresponding to GOS, peak-a =  3’-silayllactose.  
Quantification of GOS and other oligosaccharides 
Concentration of oligosaccharides in serum and urine at day 3  
In order to investigate the absorption of oligosaccharides through the porcine intestinal 
system, quantification of GOS structures observed in serum and urine samples was 
conducted using CE-LIF. In Table 1, GOS ref., serum and corresponding urine samples of 
three piglets fed on a GOS diet (S-A1-3 and U-A1-3, respectively), and serum (S-A4) 
lacking the corresponding urine sample are reported. The total GOS concentration in sera 
was: 34.1, 5.3, 31.1, and 21.2g/mL (S-A1-4, respectively). The GOS concentration in 
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urine was 0.9, 0.9 and 0.6 g/g creatinine (U-A1-3, respectively), as shown in Table 1. The 
most abundant GOS structures referred to trimers (59.6-67.1 and 56.4-58.3% w/v in serum 
and in urine, respectively, Table 1), followed by tetramers (25.6-35.5 and 31.6-33.3%), 
pentamers (4.6-8.1 and 7.6-8.3%), and hexamer (1.8-2.5 and 2.0-2.7%).The concentration 
of GOS in serum of piglet A2 was lower when compared to other serum samples. This 
could be possibly explained by a different timing of sample collection or different eating 
behavior of this piglet. GOS concentration in the corresponding urine sample showed GOS 
concentration with the same order of magnitude as the other analyzed urine samples. 
Although the relative amounts of GOS DP structures observed in the biological samples 
could be related to GOS composition as present in the piglet diet, not all GOS structures as 
present in GOS ref. were detected in piglet serum and urine. These observations can 
suggest absorption and/or early breakdown of specific GOS structures in the piglet small 
intestine. Literature describes in vitro passage of GOS through cell monolayer depending 
on GOS molecular size and structure, supporting our findings.14 Nevertheless, non-
digestible oligosaccharides are reported to be fermented already in the upper tract of piglets 
intestine, while in human, metabolization of prebiotic fructo-oligosaccharides in the last 
part of the small intestine was described.40-42 
Detection and concentration of oligosaccharides in piglet serum and urine at 26 
days 
In order to investigate the absorption and excretion of oligosaccharides in a more mature 
intestinal system, 3 serum and urine samples from piglets fed 26 days on GOS or control 
diet were analyzed. In Table 2, presence, concentration g/ml) and relative proportion of 
GOS structures in serum and urine samples of piglets fed on GOS diet for 26 days (S-B1-3, 
U-B1-3, respectively) detected by CE-LIF are shown. Piglets serum samples showed an 
average concentration of GOS of 16.1 g/ml, while in urine 0.9 g GOS/g creatinine was 
detected, comparable with values at day 3. GOS-DP3 were present in larger proportion in 
serum and urine samples from day 26 compared to day 3, since on average 70.6% of GOS-
DP3 on total GOS was detected. GOS-DP4-6 at day 26 were present in the same order of 
magnitude in serum and urine samples, confirming the trend of samples at day 3. Also at 
day 26, the presence of GOS-DP3-4 was confirmed by mass analysis (data not shown). 
Since no marker was included in the feeding trial, accurate quantification of GOS absorbed 
in the small intestine could not be finalized. However, taking the estimated feed intake per 
day into account, a very rough estimation of the GOS absorption could be obtained. 
Overall, the absorbed GOS in the circulation was estimated to be approximately 0.1% of 
the daily GOS intake, both at day 3 and 26 of the feeding trial. In this study, presence of 
dietary oligosaccharides in piglets body fluids was proven using two different techniques. 
Specific oligosaccharides from GOS supplementation, and milk replacer were detected in 
serum and urine of piglets at day 3 and 26 of experimental feeding. It was therefore 
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hypothesized that oligosaccharides of DP3-6 were absorbed by the piglet intestine, while 
early breakdown of specific dietary oligosaccharide structures in the small intestine could 
not be excluded.  
Table 1. Presence, concentration (g/ml in urine and g GOS/g creatinine in urine), and relative 
percentage of GOS structures as detected by CE-LIF in GOS ref., in serum, and in urine at day 3 of 
GOS diet of piglets. 
GOS ref. S-A1 S-A2 S-A3 S-A4 U-A1 U-A2 U-A3
peak number
6 14.7 0.6 0.1 0.2 − 0.004 0.003 0.002
7 49.1 10.1 1.2 8.7 5.9 0.3 0.3 0.2
8 41.3 6.3 1.1 5.5 4.2 0.2 0.2 0.1
9 18.4 − − − − − − −
10 13.9 − − − − − − −
11 25.1 − − − − − − −
12 31.5 5.7 0.8 4.8 4.2 − − −
concentration GOS-DP3 193.9 22.6 3.2 19.1 14.2 0.5 0.5 0.4
relative % 60.9 66.5 59.6 61.5 67.1 57.8 58.3 56.4
13 4.6 − − − − − − −
14 6.3 1.2 0.1 0.9 0.8 0.03 0.03 0.02
15 23.6 4.6 0.8 4.7 3.1 0.16 0.16 0.11
16 14.4 1.2 0.4 1.8 0.8 0.05 0.06 0.05
17 1.4 − − − − − − −
18 8.5 0.8 0.2 0.5 − 0.01 0.01 0.00
19 6.7 0.4 0.1 0.5 − 0.02 0.02 0.02
20 4.2 − − − − − − −
21 7.0 0.4 0.2 0.5 0.8 0.03 0.02 0.02
22 11.6 − − − − − − −
concentration GOS-DP4 88.4 8.7 1.9 8.8 5.5 0.3 0.3 0.2
relative % 27.8 25.6 35.5 28.3 25.9 31.6 31.8 33.3
23 4.4 0.5 0.1 0.6 − 0.01 0.01 0.01
24 11.4 1.6 0.1 2.0 1.0 0.07 0.06 0.04
25 4.8 − − − − − − −
26 2.6 − − − − − − −
27 3.9 − − − − − − −
28 3.5 − − − − − − −
concentration GOS-DP5 30.7 2.1 0.2 2.5 1.0 0.1 0.1 0.05
relative % 9.6 6.1 4.9 8.1 4.6 8.3 7.9 7.6
29
concentration GOS-DP6 5.2 0.6 − 0.7 0.5 0.02 0.02 0.02
relative % 1.6 1.8 − 2.2 2.5 2.3 2.0 2.7
total GOS concentration 318.2 34.1 5.3 31.1 21.2 0.9 0.9 0.6
average total GOS concentration
piglet serum (3 days) piglet urine (3 days)
22.9
concentration 
g/g creatinine
0.8
g /mL
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Table 2. Presence, concentration (g/ml in urine and g GOS/g creatinine in urine), and relative 
percentage of GOS structures as detected by CE-LIF in serum and urine at day 26 of GOS diet of 3 
piglets. 
 
 
GOS ref. S-B1 S-B2 S-B3 U-B1 U-B2 U-B3
peak number
6 14.7 0.9 0.2 0.9 0.03 0.02 0.05
7 49.1 6.0 3.1 3.5 0.22 0.31 0.35
8 41.3 3.8 3.7 3.4 0.15 0.34 0.32
9 18.4 − − − − − −
10 13.9 − − − − − −
11 25.1 − − − − − −
12 31.5 4.4 1.8 2.1 − − −
concentration GOS-DP3 193.9 15.1 8.9 9.9 0.4 0.7 0.7
relative % 60.9 67.7 71.7 72.3 60.1 67.9 65.9
13 4.6 − − − − − −
14 6.3 0.4 0.3 0.2 0.03 0.04 0.03
15 23.6 2.5 1.3 1.4 0.09 0.11 0.14
16 14.4 1.2 0.6 0.7 0.06 0.06 0.08
17 1.4 − − − − − −
18 8.5 0.6 0.3 0.2 0.02 0.01 0.01
19 6.7 0.4 0.2 0.2 0.01 0.02 0.02
20 4.2 − − − − − −
21 7.0 0.4 0.3 0.1 0.01 0.02 0.02
22 11.6 − − − − − −
concentration GOS-DP4 88.4 5.6 3.1 3.0 0.2 0.3 0.3
relative % 27.8 25.2 25.0 21.8 31.9 26.0 27.6
23 4.4 0.5 0.2 0.2 0.02 0.02 0.02
24 11.4 0.8 0.2 0.5 0.03 0.03 0.04
25 4.8 − − − − − −
26 2.6 − − − − − −
27 3.9 − − − − − −
28 3.5 − − − − − −
concentration GOS-DP5 30.7 1.3 0.4 0.6 0.04 0.1 0.1
relative % 9.6 5.8 3.3 4.5 6.8 5.1 5.3
29
concentration GOS-DP6 5.2 0.3 − 0.2 0.01 0.01 0.01
relative % 1.6 1.4 − 1.4 1.3 1.0 1.2
total GOS concentration 318.2 22.3 12.3 13.7 0.7 1.0 1.1
average total GOS concentration 0.9
concentration 
piglet urine (26 days)piglet serum (26 days)
16.1
g/mL g/g creatinine
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Intestinal fermentation of dietary oligosaccharides at day 3 and 26  
It has been demonstrated that the major part of GOS reaches the colon, where they are 
fermented by colonic microbiota.12, 20, 23 The results in this study confirm this, as it was 
shown that only a small amount of GOS was absorbed systemically. Hence, it was 
investigated whether GOS could be still determined in large intestine at day 3 and 26 of the 
piglet experimental feeding trial. Therefore, piglets fecal samples (at day 3 and 26) and 
cecal digesta samples (at day 26) were collected and analyzed. In Figure 7, CE-LIF profiles 
of oligosaccharides present in feces from piglets fed 3 days on GOS or control diet (f-A1-3 
and f-B1-3, respectively) are shown. Overall, no intact dietary oligosaccharides were 
detected in fecal samples using CE-LIF and HILIC-MSn. Based on CE-LIF analysis (Figure 
7) low abundance of oligosaccharides was found in the fecal samples both at day 3 and 26. 
The few peaks detected were not overlapping with peaks as found in GOS ref. (data not 
shown), possibly indicating an established and developed microbiota that could efficiently 
ferment GOS and other dietary oligosaccharides as shown in a previous study. 29  
Figure 7. CE-LIF electropherograms of GOS ref., oligosaccharides from feces at day 3 of GOS or 
control diet (f-A1-3 and f-B1-3, respectively), and milk replacer, DP = degree of polymerization 
based on GOS. The electropherograms were normalized on the internal standard xylose (*). 
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Alizadeh et al. reported a high bacterial load in fecal samples of piglets used in feeding trial 
described in this paper, already at the first day of piglet life.29  However, one profile (f-B1, 
Figure 7) showed high oligosaccharide abundance, thus low fermentable capability. 
Analysis with HILIC-MSn for this sample confirmed the presence of neutral hexose 
oligosaccharides (3 ≤ DP ≥ 5) hypothesized to be fermentation products of GOS. As 
reported for in vitro GOS fermentation by human fecal inocula, the high abundance of 
oligosaccharides could be explained by a difference in microbiota composition, 
accumulating oligosaccharides structures.43 For all samples, efficiency regarding 
oligosaccharide fermentation and accumulation in the fecal and cecum digesta samples was 
evaluated. Amount of oligosaccharides per gram of fecal slurries or cecal content was 
estimated, assuming the presence of exclusively neutral oligosaccharides. The 
concentration of oligosaccharides was 15 and 11 mg/g fecal slurry for piglets fed 3 days on 
GOS or control diet respectively. For samples obtained at day 26, oligosaccharide levels of 
16 and 9 mg/g cecal content, and 12 and 7 mg/g fecal slurry were found for GOS and 
control diet, respectively. Both in fecal and cecum digesta samples, trisaccharides were the 
most abundant structures. Due to the low abundance of the oligosaccharides, it was not 
possible to determine whether they were originated from milk replacer or GOS, using 
HILIC-MSn. In conclusion, oligosaccharides, such as GOS and 3’-sialyllactose, were found 
in serum and urine of piglets fed 3 and 26 days on milk formula enriched with GOS. Not all 
GOS as present in the diet were detected in blood and urine samples, suggesting absorption 
and/or consumption of specific GOS in piglet small intestine. As expected from human 
milk oligosaccharide behavior, GOS were estimated to be absorbed in small quantities 
(about 0.1% of GOS daily intake), both at day 3 and 26 of the feeding trial. Subsequently, 
GOS was found to be excreted via the urinary system, with GOS-DPs relative abundance in 
urine samples comparable with serum samples. Moreover, in piglets caecum digesta and 
feces, low levels of oligosaccharides were detected, suggesting extensive intestinal GOS 
fermentation. The discovery of GOS and dietary oligosaccharides in blood and urine of 
piglets now promote further evaluation of the systemic role of oligosaccharides in humans 
and animals.  
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Chapter 5 
In vitro fermentation of porcine milk- and 
galacto-oligosaccharides using piglet fecal 
inoculum 
 
 
 
Abstract  
In this study, the in vitro fermentation by piglet fecal inoculum of galacto-oligosaccharides 
(GOS) and porcine milk oligosaccharides (PMOs) was investigated in order to identify 
possible preferences for individual oligosaccharide structures by piglet microbiota. Firstly 
acidic PMOs and GOS with degree of polymerization 4-7 were depleted within 12 h of 
fermentation, whereas fucosylated and phosphorylated PMOs were partially resistant to 
fermentation. GOS structures containing 1-3 and 1-2 linkages were preferably fermented 
over GOS containing1-4 and 1-6 linkages. Upon in vitro fermentation, acetate and 
butyrate were produced as the main organic acids. GOS fermentation by piglet inoculum 
showed unique fermentation pattern when compared with GOS in vitro fermentation by 
human fecal inoculum with respect to preference of GOS size and organic acids production. 
In both fermentations, the same GOS linkage preference was noticed. 
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Introduction 
Milk is the first food source for infants, providing not only energy but also offering 
protection against pathogens.1 The third largest class of compounds present in human milk 
are oligosaccharides (HMOs).1 Numerous health related effects of HMOs, involving direct 
interactions with pathogen and/or indirect effects upon their fermentation by the intestinal 
microbiota have been reported.2 When human milk is lacking during the early stage of life 
of infants, cow milk based infant formula is used.3, 4 However, cow milk has a low content 
of milk oligosaccharides, therefore in many cases infant formulas are fortified with 
prebiotics such as galacto-oligosaccharides (GOS).5, 6 Prebiotics are defined as non-
digestible food ingredients that can influence the intestinal microbiota composition 
resulting in beneficial effects for the host.5, 7, 8 GOS are produced from lactose using β-
galactosidases of microbial or yeast source.9 The enzymatic reaction results in a GOS 
mixture containing oligosaccharides varying in degree of polymerization, mostly from 2 to 
8, and in types of glycosidic linkages present.5 Commonly, GOS have a glucose monomer 
at their reducing end to which multiple galactose monomers with different linkages (β1-2, 
β1-3, β1-4 and β1-6) are attached.10 GOS exhibit less structural complexity than HMOs. 
The major part of GOS resist degradation in the upper intestinal tract, consequently 
reaching the colon, as is the case for HMOs.8 In the colon, GOS enhance bifidobacteria 
growth, potentially protecting the infant against infections and pathogen development.2, 11 
Moreover, upon GOS fermentation, short chain fatty acids are produced, among which 
butyrate.12 Butyrate has been shown to be anti-inflammatory and anti-carcinogenic, also 
enhancing (in vitro) the intestinal barrier function.5, 13, 14 Recent study showed that in vivo 
GOS fermentation in young pigs (piglets) was extensive, not being conclusive on 
microbiota utilization towards individual GOS structures.15 In the present study, in vitro 
fermentation by piglet fecal inoculum was used in order to control different stages of 
fermentation, thereby focusing on the fate of individual oligosaccharides and organic acids 
produced. Oligosaccharides investigated were from porcine milk as present as primary feed 
source at early stage of piglet life and GOS. 
Materials and methods 
Acetic acid, acetonitrile (ACN), ammonium formate, formic acid, chloroform and methanol 
were purchased from Biosolve BV (Valkenswaard, The Netherlands). Butyric acid, lactic 
acid, succinic acid, maltotriose, 2-(N-morpholino)ethanesulfonic acid, 2-ethylbutyric acid, 
sodium chloride, 2-picoline borane complex and sodium hydroxide were purchased from 
Sigma Aldrich (Steinheim, Germany). Propionic acid, oxalic acid and 2-aminobenzamide 
were purchased from VWR International (Amsterdam, The Netherlands). ’-, 4’-
and’-Galactosyllactose were purchased from Carbosynth (Compton, UK), while 3’- and 
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6’- sialyl-N-acetylactosamine, 3’-fucosyllactose, lacto-N-(neo)tetraose and lacto-N-
(neo)hexaose were purchased from Dextra (Reading, UK). 3’- and 6’-Sialyllactose and 
lacto-N-fucosylpentaose were purchased from Sigma Aldrich. Water was filtered using a 
Milli-Q water purification system (Millipore, Darmstadt, Germany) and it was referred to 
as water in the text. Vivinal GOS Easy Drying Syrup (FrieslandCampina Domo, Borculo, 
The Netherlands), dry matter (DM) 75%, with GOS 72%, lactose 23%, glucose and 
galactose together 5% on DM, is referred to in the text as GOS. 
Oligosaccharide extraction and separation 
Porcine milk oligosaccharides (PMOs) from porcine colostrum (37 mL) 
(Proefaccommodatie de Tolakker, Utrecht University, Utrecht, The Netherlands) were 
extracted, freeze-dried and dissolved in water (70 mg/mL), and subsequently separated 
using Size Exclusion Chromatography (SEC) as reported elsewhere.16 Collection of 103 
fractions (7 mL each) started after 0.27 column volume (CV) and fractions were collected 
during 0.8 CV, as described before.16 In total, 4 runs were performed with an injection 
volume of 2.86 mL each injection. Afterwards, the fractions were pooled and freeze dried: 
pool 1: fraction 290 - 500 mL, pool 2: fraction 501 - 697 mL, pool 3: fraction 698 - 719 
mL, pool 4: fraction 720- 741 mL, pool 5: fraction 742 - 770 mL. The freeze-dried pools 
were dissolved in 36 mL water. For each pool, 1 mL was used for oligosaccharide 
characterization, while the remaining volumes were mixed and freeze dried again to obtain 
porcine milk oligosaccharides (PMOs) with a reduced amount of lactose. 
Fermentation of GOS and PMOs by piglet fecal inoculum  
Culture medium  
The culture medium was based on a modified simulated ileal environment medium (SIEM), 
not containing carbohydrates prepared as reported elsewhere.17 The pH was set at 6.0 using 
MES buffer. All the culture medium components were provided by Tritium Microbiology 
(Veldhoven, The Netherlands). 
Fecal inoculum 
Inoculum for the in vitro fermentation was obtained from fecal material from 3 Dutch 
Landrace piglets (age of 3 weeks). The piglets were fed on porcine milk over the feeding 
period, combined with pig formula (de Heus, Ede, The Netherlands) for the 2nd day to the 
8th day of life. From the 9th day of life until the end of the 3 weeks the piglets received 
pellets (de Heus). Immediately after defecation, fecal material from each piglet was 
collected in eppendorf tubes, which was immediately put into an insulated box with crushed 
ice and afterwards stored at -80°C. The piglet fecal inoculum was prepared as described 
elsewhere, with some minor modifications.18 Feces (± 100mg) of three piglets were pooled 
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after defrosting in an anaerobic cabinet (gas phase: 96% N2 and 4% H2). The pooled feces 
were diluted 6 times (w/v) with sterilized 0.9% (w/v) NaCl solution and subsequently 
homogenized using a vortex. The homogenization was facilitated by the addition of sterile 
glass beads. The fecal solution was added to the culture medium in a 20 mL flasks at a 5:82 
(v/v) ratio, in order to obtain the final inoculum. Afterwards, the bottle was closed with 
rubber stoppers and aluminum caps to maintain anaerobic conditions. Next, the inoculum 
was kept overnight into an incubator shaker (Innova 40, New Brunswick Scientific, 
Nijmegen, The Netherlands) (39°C, 100 rpm) to activate the bacteria.  
In vitro fermentation 
GOS and PMOs, obtained as described above, were used as substrates for the fermentation 
by piglet fecal inoculum. The in vitro fermentation experiment was performed as described 
elsewhere with minor modifications.18 GOS or PMOs were added to the culture medium 
with a final substrate concentration of 11.1 mg/mL. The fecal inoculum was added to the 
solution containing substrate and medium in a 1:10 ratio (v/v). Control samples consisting 
of culture medium without substrate were used to monitor the background fermentation. All 
procedures were performed in an anaerobic cabinet. Flasks were closed with rubber 
stoppers and aluminum caps, and they were put into an incubator shaker (Innova 40) (100 
rpm, 39 °C). After 9, 10, 12, 24 and 48 hours of the fermentation, two times 70 µL were 
taken from the fermentation bottles with a syringe and transferred to eppendorf tubes. In 
order to inactivate fecal enzymes, eppendorf tubes were put into a boiling water bath for 5 
min and stored afterwards at -20oC.  
Characterization and quantification of GOS and PMOs 
Samples after fermentation were cleaned prior to analysis by hydrophilic interaction liquid 
chromatography with mass spectrometry (HILIC-ESI-MSn). The samples after fermentation 
were diluted 10 times in water and 150 µL were placed into a polyvinylidene fluoride 
centrifugal filter unit (0.22 µm, Merck Millipore, Amsterdam, The Netherlands) and 
centrifuged (5 min, 20000g, 20oC). Afterwards, ACN was added to the filtrate in a ratio of 
1:1 (v/v) and the samples were centrifuged (5 min, 20000g, 20oC). Supernatants were 
analyzed on a Thermo Accela Ultra High Liquid Chromatography (UHPLC) system 
(Thermo Scientific, Waltham, MA, USA.) as described elsewhere.19 In order to recognize 
GOS linkage type, HPAEC-PAD was used and the HPAEC profiles were compared with 
profiles as reported elsewhere.10, 12 Oligosaccharides standards were used for PMO 
characterization and quantification by HILIC-MSn.. Calibration curves of the corresponding 
milk oligosaccharide standards and GOS (0.002 to 0.5 mg/mL respectively) were used in 
order to quantify PMOs and GOS by mass spectrometry. Area and concentration of 
individual GOS-DP were obtained by selecting the mass range for each GOS-DP and 
taking into account the relative amount of a given GOS-DP in the total GOS sample. If no 
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corresponding standards for neutral PMOs were available, GOS with a comparable DP was 
used for the calibration curve. The curves fitting the PMO standards showed a linear 
correlation with R2 of 0.90-0.99, while the curves fitting the GOS-DPs showed a linear 
correlations with R2 of 0.98-0.99. 
Organic acid analysis 
In order to quantify acetate, propionate and butyrate produced during the fermentation, GC 
analysis was performed as described elsewhere with minor modifications.12 Samples after 
fermentation were diluted 10 times with water. Aliquots (50 µL) and short chain fatty acids 
(SCFAs) standards (0.01-3 mg/mL) were mixed with 0.15 M oxalic acid (50 µL). The 
solutions were kept for 30 min before addition of 0.025 mg/mL 2-ethyl butyric acid as 
internal standard in water (143 µL). In order to analyze succinic and lactic acid, high 
performance liquid chromatography with refractive index detection was performed as 
described elsewhere.12 
Results and discussion 
Fermentation of porcine milk oligosaccharides (PMOs)  
As a result of rapid colonic bacterial colonization, piglets can extensively ferment dietary 
fibers.19-23 GOS and porcine milk oligosaccharides (PMOs) present in the diet of piglets are 
almost completely fermented in the colon, resulting in trace amounts of oligosaccharides 
present in the feces other than intact GOS or PMO structures.15, 19 Similarly as found for 
dietary fibers, piglets intestinal fermentation of GOS is suggested to start already in the 
small intestine and to continue extensively in cecum and colon.22, 23 In order to study any 
preference and differentiation in speed of fermentation among GOS and PMO structures, in 
vitro fermentation was performed using piglet fecal inoculum: PMOs was chosen since they 
are present in the piglets diets through sow nursing, and GOS was chosen as it has been 
used in previous piglets feeding trial.15, 21 Prior to monitor their degradation profiles, the 
main PMOs were identified and quantified by HILIC-MSn.16 Through single ion 
monitoring, in total thirteen main PMOs representing about 77% of the total peak area, 
were identified and monitored during the in vitro fermentation. Using previously gained 
knowledge,19 PMOs identified were the neutral 3’- and 6’- galactosyllactose (3’- and 
6’-GL), lacto-N-neotetraose (LNnT), lacto-N-pentaose-I (LNP-I), lacto-N-neohexaose 
(LNnH), 2’- and 3’- fucosyllactose (2’- and 3’-FL); and the acidic 3’- and 6’- sialyllactose 
(3’- and 6’-SL), 3’- and 6’- sialyl-N-acetyllactosamine (3’- and 6’-SLN), phosphorylated 
lactose (P+ lactose) and Neu5Ac(2-6)GlcNAc(1-3)Gal(1-4)Glc. The degradation of 
individual PMOs during fermentation was indirectly expressed via the abundance of 
remaining oligosaccharides present (Figure 1). Overall, a decrease in concentration upon 
fermentation was observed for each PMO, with individual differences in degradation rate 
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(Figure 1). One exception was phosphorylated lactose, which increased in concentration 
during the first 12 h of fermentation, while being depleted completely afterwards (Figure 1 
C). The lactose present was attributed partially to the small amount of lactose still present 
after purification with SEC and partially to lactose released by bacterial degradation of 
PMOs. Lactose was the first carbohydrate to be fully fermented by the porcine microbiota, 
decreasing approximately 98% during the first 9 h of fermentation. Trimers, such as 3’-
GL, 6’-GL, 2’-FL and 3’-FL were all fermented with a different rate.  
 
 
 
Figure 1. Proportion (%) of remaining PMOs during in vitro batch fermentation by piglet fecal 
inoculum. Concentration per individual PMOs at t = 0 was set to 100%. In A) lactose and 2’-, and 3’- 
fucosyllactose (2’-, and 3’-FL) are shown; in B) 3’-, and 6’- galactosyllactose ( 3’-, and 6’-GL), 
lacto-N-neotetraose (LNnT), lacto-N-pentaose-I (LNP-I), and lacto-N-neohexaose (LNnH) are 
shown; while in C) 3’-, and 6’- sialyllactose (3’-, and 6’-SL), 3’-, and 6’- sialyl-N-acetyllactosamine 
(3’-, and 6’-SLN), phosphorylated lactose (P+ lactose), and Neu5Ac(2-6)GlcNAc(1-3)Gal(1-
4)Glc are shown. 
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The trimers 3’-GL and 6’-GL diminished about 50% of their initial concentrations in the 
first 9 h of fermentation, whereby 3’-GL is more quickly fermented than 6’-GL (Figure 1 
B). LNnH is fermented faster than LNnT and LNnP-I, decreasing 80% of its original 
concentration during 12 h of fermentation. All the neutral PMOs are almost completely 
fermented within 24 h, whereas LNnT still was not consumed completely. Most probably, 
part of the LNnT present at 24 h is released by the degradation of larger PMOs. LNnT is 
totally consumed in the subsequent 24 h by the piglet colonic microbiota. Acidic PMOs are 
fermented for 50% during the first 12 h and are fermented faster than neutral PMOs (Figure 
1, C). Surprisingly, the phosphorylated lactose (P+lactose) more than doubled in 
concentration during the first 12 h of fermentation, with a subsequent decrease to about 
50% of its starting concentration. Hypothetically, the increase of phosphorylated lactose 
could be derived from fermentation of larger phosphorylated PMOs present, although they 
were not reported so far to be present in domestic animal milk samples.19, 24 Overall, 
fermentation of acidic and neutral PMOs was almost complete in 48 h, with the exception 
of fucosylated PMOs and phosphorylated lactose. In conclusion, in vitro fermentation with 
piglet microbiota showed a rapid consumption of PMOs, with different fermentation rates 
detected for individual PMOs. Piglet microbiota firstly ferment small PMOs, such as 
neutral and acidic trimers, and afterwards neutral larger PMOs, each with its own specific 
rate. 
Fermentation of galacto-oligosaccharides (GOS)  
GOS showed to be a not easy fermentable substrate for the piglet microbiota, since 20-60% 
of the GOS-DP3-7 were still present after 12 h of fermentation. Dimers were fermented 
first, as expected from a previous investigation on GOS fermented by human fecal 
inoculum.12 Lactose was fermented faster than non-lactose GOS-DP2 structures (Figure 2). 
Lactose was introduced in the pig diet not only by nursing, but also by the cow milk based 
pig formula, presumably leading to adaptation of the piglet microbiota to lactose. On the 
contrary, GOS-DP2 were not present at any phase of the piglet diet. Hence, a slower 
adaptation of the microbiota than for lactose was expected. For GOS-DP3-7 (Figure 2), 
longer fermentation times compared with fermentation times found for dimers were 
observed (9-12 h), with different utilization rates depending on the DP. In the first 12 h of 
in vitro fermentation by piglet fecal inoculum, GOS-DP5-7 were mostly degraded (about 
30%  remaining oligosaccharides), while GOS-DP3 was still present in relatively high 
abundance (60% remaining oligosaccharides) (Figure 2). This was not observed during 12 
h of in vitro fermentation of GOS by human fecal inoculum, where about 70% of remaining 
GOS-DP4-6 and about 50% of remaining GOS-DP3 were observed.12 After 24h of 
fermentation, all GOS-DPs showed to be fully fermented without DP discrimination, 
implying piglet microbiota adaptation to the GOS substrate. As expected from GOS 
fermentation by human fecal inoculum, also piglet fecal microbiota showed preference 
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regarding specific GOS structures.12 Using HPAEC-PAD analysis, not only the decrease 
during fermentation time of GOS-DP, but also the decrease of individual GOS isomers was 
monitored. In Figure 3, GOS peaks are assigned with numbers as reported previously.25 
Isomeric GOS structures were degraded differently depending on their structures as can be 
seen for lactose and for GOS-DP2 such as Gal(1-3)Gal, Gal(1-3)Glc and Gal(1-2)Glc 
(Figure 3, numbers 2.3, 2.5 and 2.6, respectively). This observation was similar to that 
observed in a previous study, reporting that 1-2 and 1-3 linkages were more easily 
degradable than1-4 linkages during GOS-DP2 fermentation by human fecal inoculum.12 
As expected from the HILIC-MSn profile, GOS-DP3 were harder to degrade than GOS-
DP2. The trimers indicated by numbers 3.8 and 3.9 were easier to ferment by piglet 
inoculum than trimers numbers 3.4, 3.5, 3.6 and 3.7 (Figure 3), as expected from GOS 
fermentation by human fecal inoculum.25  
 
Figure 2. Proportion (area %) of remaining GOS during in vitro fermentation by piglet fecal inoculum 
as measured by HILIC-MSn. Concentrations per PMOs at t=0 were set to 100%. DP = degree of 
polymerization. 
A relevant difference between piglet and human inocula, was noticed for Gal(1-4)Gal(1-
4)Glc and Gal(1-4)Gal(1-4)Fru (numbers 3.6 + 3.7, Figure 3), which accumulated with 
an increase of 17% during the first 12 h of fermentation by piglet fecal inoculum, while 
they were easily fermentable substrates for the human microbiota.12 A similar preference 
towards the degradation of specific linkages was noticed when comparing piglet and human 
in vitro fermentation: 1-3/1-2 linkages were preferred over 1-4/1-6 linkages for GOS-
DP2-3. Literature describes human and piglet microbiota composition to be similar, mainly 
consisting of Firmicutes and Bacteriodes.26 On the other hand, differences were reported to 
occur in bifidobacteria species, relevant for GOS degradation.26 Studies reported on 
extremely low amounts of bifidobacteria species present in the gastro-intestinal tracts of 
piglets (< 1% of the total bacteria present). 26-28 When detected, certain bifidobacteria 
species present in piglet intestine could differ from the species reported in human intestinal 
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tract.26, 29 Our results indicate a difference in microbiota composition based on the 
fermentation characteristics of oligosaccharides. 
 
 
Figure 3. HPAEC-PAD chromatograms of GOS fermentation with piglet fecal inoculum, with 
structures of oligosaccharides as present in the GOS mixture (2.1-3.9) (according to Ladirat et al.).25 
DP= degree of polymerization. Peak numbers correspond to structures in the insert. 
Organic acid production upon PMOs and GOS fermentation by piglet fecal 
inoculum 
The degradation of PMOs and GOS by piglet fecal inoculum resulted in the production of 
organic acids: acetate (A), succinate (S), butyrate (B), lactate (L) and propionate (P) as 
shown in Figure 4. The molar ratios A:S:B:L:P observed after 24 h of fermentation were of 
49:1:20:2:27 and 45:1:21:4:29 for PMOs and GOS, respectively. Acetate was the most 
abundant organic acid detected after 24 h of PMOs and GOS fermentation by piglet fecal 
inoculum. Similarity acetate was the most abundant organic acid produced for GOS in vitro 
fermentation by human fecal inoculum.30 Next to acetate, also propionate and butyrate 
(Figure 4, A and B) were produced for both GOS and PMOs fermentation by piglet fecal 
inoculum, whereas mainly succinate and propionate were co-produced for GOS 
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fermentation by human fecal inoculum.12, 13 For 24 h of in vitro fermentation, GOS 
fermentation with piglet and human inoculum showed differences in A:S:B:L:P molar 
ratios: 45:1:21:4:29 and 75:10:6:2:8, for piglet and human inoculum, respectively.12, 13 
Overall, after fermentation for 24 h, butyrate was produced in higher abundance upon GOS 
fermentation by piglet microbiota than by human microbiota.  
  
Figure 4. Organic acid amount and relative concentration during in vitro fermentation of GOS (A) and 
PMOs (B) by piglet fecal inoculum and of GOS by human fecal inoculum (C); adapted from Ladirat 
et al.12 
The absolute amount of butyrate was of 1.4 and 0.7 mol/mg substrate for GOS fermented 
by piglet and human inoculum, respectively.12, 13 Comparing butyrate production upon GOS 
fermentation, it can be hypothesized that microbiota from piglet inoculum contain more 
butyric-producing bacteria than human microbiota that can ferment GOS. During 
fermentation for 24 h by piglet inoculum, about 7 and 4 mol organic acids per mg of 
substrate were produced for GOS and PMOs, respectively. Fermentation of GOS by human 
fecal inoculum resulted in about 12 mol/mg organic acids production in 24 h of 
fermentation.12 Overall, in the intestinal tract, 1010-11 and 1014 bacteria per gram of intestinal 
content for piglets and human are present, respectively.26, 31  
In summary, differently from in vivo piglet fermentation, in vitro fermentation provide the 
opportunity to observe the preference of piglet microbiota on fermentation of individual 
oligosaccharides. During in vitro fermentation, acidic PMOs and neutral PMO trimers were 
the first to be degraded followed by larger neutral PMOs. Fucosylated and phosphorylated 
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PMO were the most resistant to fermentation. Interestingly, while PMO trimers were 
quickly degraded, GOS trimers showed a slow apparent degradation rate for the first 12 h 
of fermentation. GOS trimers degradation rate was hypothesized to be influenced not only 
by utilization by the microbiota, but also by the release of trimeric degradation products 
upon fermentation of larger GOS. In addition, GOS containing 1-3 and 1-2 linkages were 
faster fermented than GOS containing 1-4 and 1-6 linkages. Major products upon PMOs 
and GOS fermentation by piglet microbiota were acetate, propionate and butyrate. 
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Research aim and approach 
Lactose-based oligosaccharides (LBOs) are reported to have beneficial biological and 
immunological effects for new-borns. LBOs are present in milk from mammals, as 
mammalian milk oligosaccharides (MMOs), or are manufactured using enzymes, as 
galacto-oligosaccharides (GOS). A lot of research has been devoted to reveal the 
composition and intestinal fate of LBOs from mother milk, the so-called human milk 
oligosaccharides (HMOs). The composition of LBOs from other milk sources originating 
for example from domestic animals and LBO fermentative fate in animal digestive tract has 
been hardly investigated. The aims of this PhD thesis are to describe the composition of 
MMOs from equine and porcine milk and to determine the fate of GOS and of MMOs from 
porcine milk during in vitro fermentation. Furthermore, LBOs in blood, urine and fecal 
samples from in vivo piglet experiments were analysed. The research described in this PhD 
thesis was part of a multidisciplinary project named ‘Immuno-modulation of 
oligosaccharides from various sources’. The approach used for this PhD thesis was the 
characterization of GOS and MMOs form equine and porcine milk using hydrophilic 
interaction liquid chromatography with mass spectrometry and capillary electrophoresis 
with laser induced fluorescence or mass spectrometric detection. The individual MMOs and 
GOS utilization and formation of their degradation products was also monitored during an 
in vitro batch fermentation using piglet fecal inoculum. The knowledge gained provides a 
basis for further research on the structure-function relationships of LBOs including 
beneficial immunological effects in mammal small and large intestine and their utilization 
by the colonic microbiota. 
Mammalian milk oligosaccharides (MMOs)  
In this PhD study, oligosaccharides from equine and porcine milk were investigated, 
comparing them with structures present in human milk. Milk samples were derived from 
sows from one breed and from mares of different breeds. One of the main conclusions of 
this thesis is that MMO structures strongly vary on the milk origin, not only with respect to 
different mammalian species, but also regarding inter-individual variation within one 
mammal species (Chapters 2 and 3). Nevertheless, some MMO structures are preserved 
through all mammalian milks. Another outcome of this PhD study is that neutral and acidic 
trimers are the most abundant milk oligosaccharides in colostrums analysed: 3’- 
sialyllactose in both equine and porcine milk (about 1 and 12 g/L, respectively), 6’-
galactosyllactose (1.3 g/L) in equine colostrum and the putative Gal(1-3)Gal(1-4)Glc 
(1.1 g/L) in porcine colostrum (Chapters 2 and 3). 
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MMO structural variation per species 
In total, 16 equine milk (EMOs) and 35 porcine milk (PMOs) oligosaccharides were 
characterized and when possible quantified. In addition, structure and quantity were 
compared with oligosaccharides from human milk (Table 1). Human milk has been 
reported to have more than 200 different HMO structures, of which more than 100 
oligomers were fully structurally elucidated.1 In Figure 1, CE-LIF profiles indicating the 
main oligosaccharides as present in human, porcine and equine colostrum are shown. 
HMOs appear to be a more complex mixture, both in number and concentration of 
oligosaccharides compared to EMOs and PMOs. When comparing the number of structures 
elucidated in EMOs and PMOs (Chapters 2 and 3), neutral and acidic structures represent 
each about 50% of the total number of characterized oligosaccharides (Table 1). During the 
MMO characterization, 7 and 13 novel structures for EMOs and PMOs ranging from DP3 
to DP6 were identified, respectively. In colostrum samples, MMO concentrations ranged 
from about 2 to 5 g/L; 7 -29 g/L, and 20-25 g/L, for EMOs, PMOs and HMOs, respectively 
(Chapters 2 and 3).1 MMOs were found to be present in equine and porcine colostrums: 
β6′- and β3′- galactosyllactose, 3′-sialyllactose, lacto-N-neotetraose (LNnT), and lacto-N-
neohexaose (LNnH). These oligomers from equine and porcine milk have not been reported 
so far to be predominantly present in human milk. Different MMO structures and levels 
present in equine an porcine milk also suggest different health-related needs from the new-
borns, depending on the species.2 
 
Figure 1. CE-LIF profiles of equine, porcine and human milk oligosaccharides (EMOs, PMOs and 
HMOs, respectively). With xylose as internal standard, L = lactose, 3’-, 6’-GL = 3’-, 6’-
galactosyllactose, 3’-SL = 3’-sialyllactose, 3’-FL = 3’- fucosyllactose, Gal(1-3)L = -
galactosyllactose, LN(n)T = lacto-N-(neo)tetraose, S-LNTa = sialyllacto-N-tetraose-a, LNFP-I/III = 
lacto-N-fucopentaose-I/III, LNDFH-I = lacto-N-difucohexaose-I, LNH = lacto-N-hexaose, (T) or 
(D)F-LNH = (tri) or (di)fucosyllacto-N-hexaose. 
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In EMOs and PMOs, a higher abundance of Type II chain (Gal(1-4)GlcNAc) 
oligosaccharides than type-I chain (e.g. Gal(1-3)GlcNAc; lacto-N-biose) was observed, 
both in number and concentration. This is the opposite to what has been found for HMO 
samples.2 Differentiation is also observed regarding the degree of sialylation and 
fucosylation of the MMOs. On the total number of structures, EMOs and PMOs were found 
to be sialylated for 50% and 43%, respectively, while HMOs were reported to be sialylated 
for 10-30%. Fucosylation of  MMOs highly vary, depending on the specie: 0%, 23% and 
50-80% for EMOs, PMOs and HMOs, respectively (Table 1). Significant variations in 
abundance of sialylation and fucosylation for HMOs have been reported.2-4  
Table 1. Overview of equine, porcine and human milk oligosaccharide characteristics. 
  
EMOs = equine milk oligosaccharides, PMOs = porcine milk oligosaccharides and HMOs = human 
milk oligosaccharides, a = Ref.1, b = Ref.2, ─ = not applicable. 
Porcine, equine and also bovine, caprine and ovine colostrums contain oligosaccharide 
structures comparable to HMOs, but also rather unique structural unit, like phosphorylated 
monosaccharides and glycolylneuraminic acid could be present.5, 6 PMOs were found to 
contain phosphorylated lactose (Chapter 3), which is absent in HMOs. Overall, this PhD 
study shows that porcine colostrum have higher concentration and larger variation in 
oligosaccharides compared with equine colostrum. Moreover, contrarily to EMOs, some 
PMOs present fucosylation in their structures.  
Mammalian milk oligosaccharides (MMOs)
EMOs PMOs HMOs
Number of MMOs
structures identified 16 35 >100a
structures overlapping with HMOs 10 19 ─
Percentage based on MMO number
sialylated structures 50% 43% 10-30%a
fucosylated structures 0% 23% 50-80%a
phosphorylated structures 0% 3% 0%a
bifidogenic factor (Gal(β1−3)GlcNAc) 19% 23% 72%b
Concentration (g/L)
total oligosaccharides 2-5 7-29 20-25a
bifidogenic factor MMOs 0.25 0.21 ─
decrease from colostrum to mature milk ─ ≈50% ≈50%
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MMO level variation per species 
When looking at the milk oligosaccharide literature, quantification of oligosaccharides is 
not simple and unambiguous in most cases. Frequently, just a signal response as obtained 
by a specific technique is given in order to describe MMO quantity.6-8 Therefore, it is 
challenging to compare MMOs described from different studies and to be conclusive on 
MMO levels. In this study an overview was made on the most abundant oligosaccharides as 
present in equine, porcine (Chapter 2 and 3) and human colostrum (literature).2 Overall, 
both neutral and acidic trimers were found to be the most abundant oligosaccharides in 
equine and porcine colostrum. Trimers have been reported to be the most abundant HMOs 
as well (as shown in Table 1, Chapter 1). The abundance of trimeric structures may vary 
depending on the species analysed. Neutral 6’-galactosyllactose (1.3 g/L), putative 
Gal(1-3)Gal(1-4)Glc (1.1 g/L) and 2’-fucosyllactose (average 2.8 g/L) were the most 
abundant oligosaccharides in EMOs, PMOs and HMOs, respectively. 3’- Sialyllactose was 
the most abundant acidic trimer in EMOs and PMOs (1 and 12 g/L, respectively), while 
both 3’-, and 6’-sialylactose (average of 0.2 and 0.9 g/L, respectively) were most abundant 
in HMOs (Chapters 2 and 3). Sialylated oligosaccharides have been found to be important 
towards pathogen protection, and may contribute to allergy prevention.9, 10 The bifidogenic 
factor Gal(1-3)GlcNAc chain (type-I chain or Lacto-N-biose) was present in EMOs and 
PMOs, covering 19% and 23% of the total number of oligosaccharides found respectively 
(Table 1). It has been shown that bifidobacteria growth preferentially on HMOs type-I 
chain structures when compared with other bacteria such as clostridia, enterococci and 
lactobacilli.11-13 Among HMO structures reported by Urashima et al., 72% of all HMOs 
contain the so-called bifidogenic factor.2  
MMO variation in time 
When investigating MMOs, the stage of lactation of the mother should be taken into 
account. In general, the highest MMOs concentration is found during the first few days of 
lactation, while in time the concentration tend to decrease.2 In this PhD study, a decrease of 
about 43% in the concentration of PMOs in porcine milk was found within 1 week lactation 
of the sow (Chapter 3). This value is comparable with decreases described elsewhere: 50% 
for both human and cow milk.3, 7 High concentrations of MMOs in the early stage of life are 
expected, since they play a key role in the health of new-borns, exerting intestinal 
protecting functions and intestinal immune system maturation.1 Lower MMO 
concentrations in mature milk, nevertheless, could be compensated by an increased milk 
intake by the suckling neonate, and to a more developed and stable intestinal system. It was 
shown for two porcine milk samples, that PMO concentration decreases within 1 week 
nursing time (Chapter 3). Interestingly, while the total PMO concentrations decrease in 
time, not all PMOs decrease accordingly. Relative abundance of acidic PMOs decreased on 
6 
CHAPTER 6 
 
98 
 
average 28%, while the relative abundance of neutral PMOs increased 34% within 1 week 
nursing time. This trend was comparable for bovine milk oligosaccharides, in which the 
predominantly present acidic milk oligosaccharides decreased 30% while the neutral 
oligosaccharides increased 50% in abundance.7 Nevertheless, more studies should be 
conducted towards the variation of MMO concentration and composition in time in order to 
have a better understanding of the role of the MMOs during different stages of nursing. 
Fate of lactose-based oligosaccharides (LBOs) in piglet  
Systemic fate of LBOs is hardly investigated. A small part of the LBOs are found in blood 
serum and subsequent in urine of the new-born as was already shown for HMOs in blood 
and urine of infants.1, 14, 15 An important conclusion from the piglet in vivo trial is that GOS 
as well as neutral and acidic oligosaccharides derived from the piglet diet were found for 
the first time both in blood and urine of GOS-fed piglets (Chapter 4). So far, literature 
reports on LBOs entering into the colon, where they are fermented by microbiota leading to 
an increase of the bifidobacteria population, lowering the pH and contributing to the 
protection of the host towards pathogen infection.16-19 In the in vitro fermentation 
experiment in which GOS was fermented by piglet inoculum, the preference of the 
utilisation of specific GOS structures was observed. GOS containing 1-3 and 1-2 
linkages were more rapidly fermented than GOS containing 1-4 and 1-6 linkages. 
Among PMOs, 3’-linked sialylated PMOs were preferred over the 6’-linked sialylated 
PMOs by piglet microbiota (Chapter 5).  
GOS in blood and urine 
Literature report on the presence of diverse HMOs in bloodstream and subsequently in 
urine of infants.20-22 In this thesis, the presence of GOS in blood and urine (body fluids) of 
piglets was proven (Chapter 4). Upon GOS diet (for 3 and 26 days) and subsequent animal 
sacrifice, piglet body fluids were analysed. Specific GOS were found in piglet body fluids 
of GOS-fed piglets, suggesting selective adsorption of GOS (Chapter 4). During their 
passage though the intestinal tract, GOS seem to be absorbed for a small part (0.1% of the 
GOS daily intake) and subsequently excreted by the urinary system. Absorption of 
components in the small intestine is possible by para-cellular and/or trans-cellular 
pathways. Para-cellular pathway is aspecific and based on a concentration gradient.23 
Trans-cellular pathways are active, receptor-mediated transportations and they allowed the 
passage of specific structures through the cell membrane.24 This hypothesis is in line with 
literature reporting the in vitro passage of GOS through cell monolayer depending on GOS 
molecular size and structure.25 Seen that comparable structures and relative abundances of 
GOS were found back in the blood for both 3 and 26 days GOS-fed piglets (Table 2), both 
active and passive transport from the small intestine to the blood circulation was 
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hypothesized, as shown for neutral HMOs.24, 26  A stereospecific and saturable uptake of 
neutral HMOs into the cells by trans-cellular pathway (trans-cytosis), together with para-
cellular transport (through tight junctions) was shown in vitro using Caco-2 monolayer.24, 26 
Having a pore size of around 4 Å, the tight junctions would allow structurally diverse 
oligosaccharides to pass the intestinal barrier.27, 28 So far, from the more than 200 annotated 
structures in human milk, only 7 neutral HMOs (fucosyllactose, lacto-N-tetraose, 
fucosyllacto-N-tetraose, difucosyllacto-N-tetraose, lacto-N-fucosylpentaose-I and-II, and 
difucosyllacto-N-hexaose) and 4 acidic (3’, and 6’-sialyllactose, 3’-, and 6’-N-
acetyllactosamine) HMOs were found in blood and urine samples from babies.27, 28 In this 
PhD thesis, it is suggested that GOS can pass the intestinal barrier through both the para- 
and trans-cellular pathway (Chapter 4), as suggested for HMOs. Since piglets have been 
shown to have oligosaccharides fermentation already in the upper intestinal tract 29, 30, it can 
be hypothesized that specific structures have been already utilized in the ileum (distal small 
intestine), resulting in a slight modified oligosaccharide composition when compared with 
oligosaccharide composition in the proximal small intestine. Therefore, depletion before 
absorption of specific GOS could not be excluded.  
Table 2. Overview of average GOS-DP relative abundance referred to total GOS-DP3-6 found in 
serum and in urine, of 3 and 26 days GOS fed piglets. 
 
DP = degree of polymerization. 
Excretion of GOS in urine was also monitored. Comparing the relative abundance of 
urinary GOS-DPs with GOS-DPs present in the feed as well in the blood, the same order of 
magnitude was found as exemplified in Table 2. HMOs presence in urine has been 
suggested to have protective function against urinary tract infections by blocking pathogen 
adhesion to the epithelial cell wall.4, 31 Although the relative abundance of GOS-DPs was 
comparable, some GOS individual structures present in the blood were not present in urine 
samples (Chapter 4). It could be hypothesized that either the concentration of the specific 
structure was under the limit of detection for the techniques used, or that specific structures 
were utilized systemically. The mechanisms of GOS absorption and excretion remain still 
open for future investigation, although it can be hypothesized that GOS can follow similar 
fate as neutral HMOs. 
GOS ref. serum urine serum urine
DP3 60.9 63.7 57.5 70.6 64.6
DP4 27.8 28.8 32.2 24.0 28.5
DP5 9.6 5.9 7.9 4.5 5.7
DP6 1.6 2.2 2.3 1.4 1.1
average relative % GOS 
26 days 3 days
GOS feeding
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GOS fermentation in vivo  
It was already shown by in vitro experiments that GOS can directly affect intestinal 
epithelial cells by improving the intestinal barrier function via accelerating tight junction 
assembly.32 In vitro experiments, however, represent an extreme simplification of the 
mammalian intestinal epithelial barrier. Therefore, it was evaluated whether the neonatal 
piglet could be an appropriate model to study GOS intestinal fate and function.33 After birth 
and 24-48 h sow nursing, piglets were fed on a formula diet with or without GOS for 3 or 
26 days.33 After sacrificing the piglets, samples from saliva and the intestinal tract were 
analysed. From this study, we can conclude that GOS represent a bioactive mixture with 
multiple functions (yet unpublished results33). GOS were shown to be a specific substrate 
for bifidobacteria, to improve the intestinal architecture and to affect barrier integrity, 
whereas GOS can also influence the mucosal immune system by increasing salivary IgA 
(immunoglobulin-A) production. After 26 days fed on a GOS diet, bifidobacteria species in 
piglet faeces were not decreasing in number, as was observed for the piglets fed on the 
control diet. Interestingly not all bifidobacteria grew on GOS while among the species 
stimulated to grow, also intestinal human type-bifidobacteria were found. This finding is in 
line with data from experiments with HMOs illustrating that B. infantis grew on HMOs 
while B. longum did not.1 
Extensive GOS in vivo fermentation was correlated with extremely low amounts of 
oligosaccharides in fecal and cecal samples (Chapter 4). GOS-fed piglets had a lower cecal 
pH after 26 days than at day 0 of GOS-diet, potentially protecting the piglets from 
pathogenic bacteria and increasing mucin production.19, 33 The lower cecal pH after 26 days 
of GOS diet indicates organic acid production including butyrate. The content of the latter 
was found to be higher when compared with the control group (about 1280 and 950 mol/L 
for GOS-fed and control-fed piglets, respectively).33 Next to effects of GOS on the 
intestinal microbiota  composition, also an effect of GOS on the intestinal wall was shown: 
after 26 days on the GOS-diet, piglets intestinal-villi were found to be thicker than villi of 
piglet fed on control diet, possibly improving digestion/adsorption of nutrients.33 GOS 
improved the intestinal barrier function, directly up-regulating gene expression of tight 
junction proteins, helping the intestinal integrity of different parts of the intestine.33 
Moreover, in saliva of piglets fed 26 days on GOS-diet, an increased IgA concentration was 
found, showing an influence of GOS on the immune-system.33 In this PhD thesis, it was 
shown that piglet was a successful model to investigate the effect of GOS in the intestinal 
system. However, one limitation of the pig as a model was that the intestinal fermentation 
of GOS was so extensive that it was not possible to investigate any preference of the 
microbiota for specific GOS structures. For this reason, the pig in vivo model was extended 
with an in vitro model to monitor intestinal microbiota fermentation behaviour. 
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GOS fermentation in vitro  
Piglet intestine colonization was shown to be influenced by mode of delivery, environment 
and feeding.26, 34, 35 Therefore, the in vitro batch fermentation was carried out with pooled 
piglet fecal inoculum since a pooled fecal inoculum can better represent larger and random 
microbiota communities.18 Pooling microbiota will lower the expected high inter-individual 
variation and can create also the possibility to investigate the bacteria competition for the 
same substrate and cross-feeding interactions.18 Cross-feeding is the base on which butyrate 
production lies: bifidobacteria themselves have no genetic potencial concerning butyrate 
production pathways. However, bifidobacteria carbohydrate-fermentation create 
metabolites such as acetic acid, that can enhance the growth of butyric-producing 
bacteria.36 In this way, GOS exert both an bifidogenic and butyrogenic effect. During 24 h 
GOS in vitro fermentation with piglet inoculum, acetate was the most abundant product 
among the organic acids (3 mol/mg substrate) (Chapter 5). Acetic acid has been also 
reported to be the major fermentation product for GOS in vitro fermentation by human 
fecal inoculum (9 mol/mg substrate).37 At the same fermentation time point, butyrate was 
abundantly present (about 1.4 mol/mg substrate) for fermentation by piglet inoculum. The 
high abundance of butyrate together with a consumption of acetate during the last 24 h of 
fermentation of GOS with piglet inoculum could be an indication of the presence of 
bacteria capable to use external acetate for butyrate production.36 The fecal microbiota 
composition during fermentation should be investigated in order to have a better 
understanding of the microbiota changes in time upon GOS fermentation in piglets. 
Although during the in vivo experiment all oligosaccharides were utilized very efficiently, 
our in vitro fermentation study showed the preferred utilization of individual GOS and 
PMOs by the piglet microbiota. Moreover, during in vitro fermentation studies using piglet 
microbiota, the preference of GOS containing 1-3 and 1-2 linkages above 1-4 and 1-6 
linkages and of 3’-sialylated PMOs above 6’-sialylated PMOs was shown (Chapter 5).  
Characterization of lactose-based oligosaccharides  
In this thesis capillary electrophoresis and liquid chromatography were used in order to 
characterize lactose-based oligosaccharides (LBOs). Technique related characteristics are 
shown in Table 3. One of the main conclusions of this PhD study is that hydrophilic 
interaction liquid chromatography (HILIC) with on line UV and mass spectrometry 
detection is the preferable technique when compared with capillary electrophoresis with 
fluorescence and mass spectrometry detection when analysing complex oligosaccharides 
mixtures. Capillary electrophoresis with laser induced fluorescence detection (CE-LIF) was 
investigated by Albrecht et al, and has been shown to have good peak resolution, sensitivity 
and reproducibility, being a valuable method to quantify reducing oligosaccharides.3 
Nevertheless, CE-LIF peak identification strongly depends on available standards that are 
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currently still complex to synthetize.38 When coupled to mass spectrometry (MS), the 
capillary is increased in length, consequently decreasing peak separation and increasing 
peak broadening. Moreover, the label used (APTS) present 3 possible charge states of the 
ionised oligosaccharides, hindering oligosaccharide characterization during mass 
(fragmentation) analysis. The CE technique, therefore, required a compromise between 
mass data acquisition and (isomer) separation. HILIC using a BEH-amide column has been 
shown to be a suitable tool for acidic oligosaccharides isomer separation and 
characterization in previous studies.39, 40  
Table 3. Overview of the techniques used in this study for characterization of oligosaccharides. 
n.a. = not applicable, − = poor, + = sufficient, ++ = good, +++ = very good, and * = conditions as 
described in Chapter 4, OS = oligosaccharide. 
Therefore, within this PhD project, the separation of both neutral and acidic LBOs on a 
BEH-amide column has been investigated (Chapters 3, 4 and 5). The GOS separation was 
shown to depend on the pH and gradient used and GOS isomers could be partly separated, 
while on-line MS (fragmentation) analysis enabled the identification of GOS (isomers) 
without any pre-fractionation. In order to obtain an optimal GOS-isomer separation, 
different conditions were tested, as shown in Figure 2. From different conditions tested, pH 
4.5 showed to be most optimal for isomer separation. Porcine milk oligosaccharides 
note note note note
Oligosaccharides
labelled yes APTS yes APTS no yes 2-AB
reducing yes yes yes yes
non-reducing no no yes no
Technique
isomer separation +++ ─ ++ ++
peak resolution +++ ─ ++ +++
structural characterization +
with
standards
++
only 
reducing OS
++
reducing end
recognition 
still 
challenging
+++
simpler 
spectra
compared 
with
HILIC-MS
multiple peak per compound no yes
multiple 
charged OS, 
APTS 
dependent
no no
MS ionization n.a. ++
multiple 
charged OS, 
APTS 
dependent
++
OS structure
dependent
+++
quantification
absolute,
molar
relative 
relative and
absolute
OS structure 
and
standard 
availability 
dependent
absolute,
molar
UV based
CE-LIF HILIC-UV-MS*HILIC-MS*CE-MS
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(PMOs) could be separated successfully using the same gradient and separation conditions 
as used to separate GOS. Characterization of GOS isomers still remain challenging in 
HILIC-MSn, due to quite some peak overlap at DP≥4. Mammalian milk oligosaccharides 
(MMOs), on the other hand, being built up by different types of monomers, results in a 
structure-specific mass fragmentation. This facilitates isomeric recognition of MMOs, even 
when peak overlap occurs. MS quantification of LBOs still represents a challenge, since 
even isomeric structures appear to have a different ionization behavior.41, 42 Moreover, 
when acidic and neutral molecules are both present in a mixture, as in case of MMOs, 
selective-suppression of the signal in MS is possible.43  
  
Figure 2. GOS separation by HILIC-MS using a BEH-amide column at pH 3, 4.5 and 10. DP = 
degree of polymerization. 
During mass spectrometry measurements in positive mode, for example, acidic structures 
would give lower signals than neutral structures.43 In this way the use of specific standards 
is needed for quantification, while such standards are not always commercially available. In 
order to overcome ionization- and standard-dependent quantification in liquid 
chromatography, labelling procedures involving fluorescent labels have been developed. As 
mentioned in Chapter 1, different labels have been reported for oligosaccharides analysis 
and all labelling mechanisms rely on reductive amination. GOS were labelled with 2-
aminobenzamide (2-AB), using labelling conditions as reported elsewhere.44 2-AB is 
suitable for fluorescent detection, nevertheless it was also shown to be suitable for UV 
detection (254 nm ).45 As shown in Figure 3, peak shape and resolution of labelled GOS 
isomers make their separation on a BEH-amide column at pH 4.5 successful. The GOS 
shown in Figure 3 had a reduced amount of glucose, galactose and lactose compared with 
GOS presented in Figure 2, and was therefore called ‘purified GOS'.  
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Figure 3. Separation of 2-AB labelled purified GOS on HILIC-MS using a BEH-amide column pH 
4.5. 2-AB-DP refers to labelled GOS of a given degree of polymerization (DP), while DP refers to 
unlabelled GOS of the given DP. 
From both their elution time and from MS analysis, unlabelled GOS-DP4-7 were identified 
in the labelled GOS sample (Figure 3), probably indicating the presence of 1-1 linked 
oligosaccharides that indeed could not be labelled. In order to evaluate 2-AB GOS labelling 
efficiency, different oligosaccharide concentrations (5-1000 nmol), temperatures and 
labelling times were tested with respect to labelling efficiency. Labelling efficiency didn’t 
change dramatically when using different conditions. Therefore, in future oligosaccharide 
investigations using 2AB-labelling, a minor amount of substrate (100 nmol) and a lower 
temperature (40oC) when compared with literature (200 nmol and 65oC) should be used, 
accepting the obvious fact that non-reducing oligosaccharides will not be labelled.6, 46 As 
summarized and exemplified in Table 3, currently used techniques have both advantages 
and drawbacks. At the moment, HILIC-(UV)-MS seems to be the most flexible and robust 
analytical tool for LBO analysis.  
Future perspectives  
In this thesis, MMOs different from human milk oligosaccharides (HMOs) were reported. 
High inter-individual variation regarding the presence and concentration of milk 
oligosaccharides in equine and porcine milk have been described. This information can be 
taken into account in future experiments involving domestic animal milk oligosaccharide 
analysis, and may even be used to evaluate current literature with another view. The 
approaches and methods developed during this thesis research are now available to 
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fingerprint milk samples from various origin in a semi-high throughput manner in order to 
make an inventory on type and level of oligosaccharides present. While such information 
on breed and animal variation level has been made available for equine colostrum in this 
study, for colostrum and milk from other animals this information is still lacking. This also 
holds for the milk oligosaccharide composition during the weaning period of new-born 
animals.   
As was demonstrated in our research, the direct analysis of complex MMO mixtures is 
challenging due to the low abundance of some oligosaccharides. Although present in low 
abundance, specific oligosaccharide structures might be relevant both for triggering 
biological functions and for being (preferably) fermented by colonic microbiota. Pre-
fractionation on size prior to identification showed to be quite successful, but separation on 
charge should also be considered. In addition, an ongoing search for improving the 
oligosaccharide separation methods developed should be pursued to face the complexity 
and natural variation of mammal milks. An issue to be addressed is the separation and mass 
spectrometry investigation of phosphorylated oligosaccharides, since this class of 
oligosaccharides has been hardly investigated.  
Methods presented in this thesis research also revealed the importance of being able to 
monitor fermentation products in animal digesta and in vitro fermentation liquids. 
However, due to the presence of various types of dietary oligosaccharides in milk and feed, 
in addition to unknown/novel glycosidic degradation products from milk and feed, method 
development and fine-tuning could be necessary here as well. By investigating colonic fate 
of dietary oligosaccharides, also the composition and variation in time and per individuals 
of the microbiota could be addressed and explained.  
During our research, the presence of dietary oligosaccharides in blood and urine of piglets 
was shown for the first time. However, the complete identification and accurate 
quantification of all different oligosaccharides in blood and urine is needed to fully 
understand both absorption and secretion mechanisms, and also to make progress in 
understanding their systemic functions. Progress being made in mass spectrometry (both 
quantitative MS and enhanced understanding of mass fragmentation mechanisms) will 
contribute in the understanding of the presence of oligosaccharides and their metabolites in 
blood and urine.   
Awareness of the important role of milk oligosaccharides with respect to their biological 
and immunological functions in new-born intestinal and systemic health increased by the 
enormous scientific research done on milk so far. Therefore, efforts have been dedicated in 
manufacturing oligosaccharide mixtures resembling the composition of the natural milk 
oligosaccharides better. As example, a mixture containing N-acetylgalactosaminyl-lactose 
(GlcNAc(β1-3)Gal(β1-4)Glc), representing a MMO precursor, has been synthetized from 
lactose using β-N-acetylhexosaminidases, whereas a mixture containing GOS decorated 
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with sialic acid has been manufactured using a trans-sialidase enzyme.47, 48 Analytical tools 
for identification and quantification of several types of oligosaccharides within complex 
oligosaccharide mixtures developed and investigated in our research can be used to 
investigate the novel manufactured oligosaccharide mixtures.  
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Summary 
Lactose-based oligosaccharides (LBOs), including mammalian milk oligosaccharides 
(MMOs) and galacto-oligosaccharides (GOS), have been shown to have beneficial effects 
on the intestine of infants. In Chapter 1, the structural characteristics, concentration and 
variation of MMOs of different mammalian species are described, in addition to some 
health benefits. Human milk has been shown to contain the highest number of structures as 
well as the highest concentrations of oligosaccharides compared with some domestic 
mammalian milks. Milk from domestic animals have been shown to have a unique MMO 
pattern. The composition of MMOs depend on the mammal lactation stage and 
concentrations of MMOs becomes lower in time as is the case for human milk. However, 
the variation in MMO composition for milk from domestic animals in time, between breed 
and between individuals has been hardly investigated.  
In Chapter 2, MMOs present in equine milk is described. Equine milk oligosaccharides 
(EMOs) were analysed by capillary electrophoresis with fluorescence detection (CE-LIF), 
by hydrophilic interaction liquid chromatography with mass spectrometry (HILIC-MSn) in 
combination with enzymatic digestion using exo-glycosidases. In total, 16 EMOs were 
recognized, seven of which were novel for EMO literature. EMOs found showed a 63% 
overlap with structures present in human milk. EMOs present in colostrum samples from 4 
different horse breeds ranged from 2.12 to 4.63 g/L. Trimeric oligosaccharides were shown 
to be most abundant structures in all colostrum samples from all breeds. Interestingly, 
differences were found for the composition in milks from different breeds. A large inter-
individual EMO variation was also found between animals within the same breed.  
Also porcine milk oligosaccharides (PMOs), as present in pig colostrum and mature milk, 
were investigated as described in Chapter 3. In porcine colostrum, in total 35 PMOs were 
recognized of which 13 have not been reported for pig colostrum before. As expected from 
the horse milk study, variation regarding PMO type and concentration was observed among 
the colostrum samples. During the first week of lactation, a 43% decrease in PMO 
concentration was found. Interestingly this decrease was not found for all oligosaccharides 
in the same way: where neutral PMOs increased in concentration in time, the opposite was 
observed for acidic oligosaccharides. After PMO ingestion by piglets, it was investigated 
whether it was still possible to detect intact PMOs in piglet fecal samples. Overall, already 
after one day of birth, only very few intact PMOs were found in fecal samples of piglet 
suggesting extensive PMO fermentation already at early stage of piglet life.  
In Chapter 4 the presence and relative abundance of dietary oligosaccharides in blood, 
urine and fecal samples obtained from an in vivo piglet feeding trial are described. 
Oligosaccharides were investigated by liquid chromatography mass spectrometry and 
capillary electrophoresis with fluorescence detection. Overall, 3’-sialyllactose naturally 
occurring in the piglet diet and specific GOS structures with a degree of polymerization 
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(DP) from 3 to 6 were detected in piglet blood and urine. Despite the fact that during the in 
vivo trial no digestion marker was used, estimation of GOS present in the samples was 
attempted. At day 3 and 26 of GOS diet, about 0.1% of the GOS daily intake was found in 
piglet blood samples. Therefore, only a minor part of GOS intake was present systemically. 
GOS structures found in blood were also traced back in urine with the same relative 
abundance. Most of dietary GOS will end up in the large intestine where they can be 
fermented by the microbiota. In piglet fecal samples, all GOS were found to be fully 
fermented, illustrating an extensive GOS intestinal fermentation.  
The quick PMO and GOS fermentation in vivo in piglets did not provide any information 
on the preference of utilisation of individual GOS by the colonic microbiota. In Chapter 5,   
the in vitro batch fermentation of PMOs and GOS using piglet fecal inocula is described. 
Overall, acidic PMOs and neutral trimeric PMOs were the first structures to be utilised by 
the microbiota. In addition, fucosylated and phosphorylated PMOs were shown to be more 
resistant to fermentation. In the first 12 h of fermentation, GOS with DP5-7 were depleted 
about 70% their initial concentrations, whereas GOS-DP3 showed to be depleted for about 
40% their initial concentration. The relatively high abundance of GOS-DP3 was attributed 
to the fermentation of larger GOS structures. During GOS fermentation, piglet microbiota 
firstly fermented GOS having 1-2 and 1-3 linkages and afterwards GOS having 1-4 and 
1-6 linkages. Similar GOS linkage preference has been shown for in vitro batch 
fermentation using human fecal inoculum. PMOs and GOS fermentation resulted in organic 
acids production, with acetate and butyrate as the major products.  
In Chapter 6, novel information acquired during the PhD thesis are discussed and future 
perspectives on MMOs and GOS investigation are described. Oligosaccharides from equine 
and porcine milk are compared with oligosaccharides as found in human milk and other 
domestic animal milks. Possible EMO and PMO bio-functions are addressed, relating them 
to bio-functions reported for human milk. The relevance of oligosaccharide analyses in 
blood and urine and the observed presence of oligosaccharides in these biological samples 
are discussed. Since HMOs were also reported to be present in blood and urine of infants, 
knowledge gained on GOS in piglet blood and urine is correlated with HMO literature. 
GOS and PMOs are described regarding their in vitro fermentation patterns and organic 
acid production and compared with existing knowledge on non-digestible oligosaccharides 
fermentation using pig and human inocula. It is concluded that the in vitro fermentation 
studies, piglet inoculum showed a unique oligosaccharide fermentation pattern, increasing 
the knowledge on oligosaccharide intestinal fate in piglets. At last, methods developed in 
this thesis research as well as recent developments for the analysis of oligosaccharides in 
milk and mammal biological samples are discussed and advantages and disadvantages 
highlighted. Liquid chromatography with on line UV and mass spectrometry detection is 
considered to be the most promising analytical method for LBOs analysis.  
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